ClinicalTrials.gg
CompletedNCT02592434Updated Apr 13, 2020Results posted

Efficacy Study Of Tofacitinib In Pediatric JIA Population

A Phase 3 interventional study of CP-690,550 (tofacitinib) and placebo in Juvenile Idiopathic Arthritis, sponsored by Pfizer. Completed at 103 sites in 14 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-04-13.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
225
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Arthritis, Juvenile by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Arthritis, Juvenile · Pfizer.

Started
2016
the only one that year
Phase 3
4 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Arthritis, Juvenile by Pfizer, this one is the only one that started in 2016, is one of 4 in phase 3, and was the 8th registered.

Arthritis, Juvenile

366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

1 of the 10 studies in Arthritis, Juvenile by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by Pfizer, or all of them as a file.
02

Study summary

Evaluate efficacy, safety and tolerability of tofacitinib in pediatric JIA patients.

Read the detailed description

This is a randomized withdrawal, double blind, placebo controlled study of pediatric subjects (2 to \<18 years of age) with JIA. The primary objective is to compare the efficacy of tofacitinib versus placebo for the treatment of signs and symptoms of JIA at Week 26 of the double blind phase as measured by the percentage of subjects with disease flare (according to PRCSG/PRINTO Disease Flare criteria) after Week 18 of the open label run in phase.All eligible subjects enrolled in the study will initially receive open label tofacitinib for 18 weeks (run in phase). At the end of the 18 week run in phase, only subjects who achieve at least a JIA ACR 30 response will be randomized to the 26 week double blind, placebo controlled phase. Subjects who do not achieve a JIA ACR 30 response at this time point will be discontinued from the study. In addition, subjects who experience a single episode of disease flare at any time during the study (including the open label run in and double blind phase) will also be discontinued from the study. All subjects participating in this study, including those discontinued from the study, will have the option, if eligible (based on inclusion and exclusion criteria), of enrolling in the tofacitinib JIA long term extension study (A3921145).

Subjects who are eligible for the 26 week double blind phase will be randomized (1:1 ratio) to either active tofacitinib or placebo. For subjects with polyarticular course JIA (ie, extended oligoarthritis, polyarthritis RF+, polyarthritis RF , systemic JIA with active arthritis but without active systemic features), randomization will be stratified by JIA category and baseline CRP (normal, above normal). For subjects with psoriatic and enthesitis related arthritis, randomization will be stratified by JIA category.

Approximately 210 subjects will be enrolled in the open label run in phase. Among subjects with polyarticular course JIA, stratification will target at least 50% with a baseline CRP above the upper limit of normal. The first cohort (ie, polyarticular course JIA) will have at least 170 subjects enrolled in the run in phase with the minimum number of JIA categories as follows: 24 with extended oligoarthritis, 20 with polyarthritis RF+, 62 with polyarthritis RF-, and no minimum for subjects with systemic JIA with active arthritis but without active systemic features. Additional cohorts (ie, psoriatic and enthesitis related arthritis) will include a minimum of 20 subjects with psoriatic arthritis, and 20 subjects with enthesitis related arthritis. The overall target minimum number of subjects to be enrolled in the study by age is as follows: 20 subjects 2 to \<6 years, 20 subjects 6 to \<12 years, and 20 subjects 12 to \<18 years. The duration of subject participation among those who complete the study (without discontinuation) is expected to be approximately 44 weeks.

03

Conditions studied

  • Juvenile Idiopathic Arthritis

Keywords

  • Arthritis
  • Pediatric
  • Long-term
  • JIA
  • polyarticular
  • CP-690,550
  • tofacitinib
  • Xeljanz
04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female aged 2 to \<18 years.
  2. Must meet International League Against Rheumatism (ILAR) JIA diagnostic criteria for one of the following categories with active disease for at least 6 weeks:

    • Extended oligoarthritis;
    • Polyarthritis (RF+);
    • Polyarthritis (RF-);
    • Systemic JIA with active arthritis but without active systemic features in the prior 6 months and at the time of enrollment;
    • Psoriatic arthritis;
    • Enthesitis related arthritis. Subjects with polyarticular course JIA (ie, extended oligoarthritis, polyarthritis RF+, polyarthritis RF , systemic JIA with active arthritis but without active systemic features) must have a minimum of 5 active joints (an active joint is defined as a joint with swelling or, in the absence of swelling, limited range of motion accompanied by either pain on motion or tenderness) at screening and baseline to be eligible for study entry.

    Subjects with psoriatic or enthesitis related arthritis must have a minimum of 3 active joints (an active joint is defined as a joint with swelling or, in the absence of swelling, limited range of motion accompanied by either pain on motion or tenderness) at screening and baseline to be eligible for study entry.

    Treatment with stable doses of a Non Steroidal Anti inflammatory Drug (NSAID) and/or a stable dose of an oral , and/or a stable dose of methotrexate is permitted.

    For subjects receiving an oral glucocorticoid: Glucocorticoids may be administered at a maximum dose of 0.2 mg of prednisone equivalent per kilogram per day or 10 mg per day for ≥ 2 weeks before baseline, whichever is lower.

    For subjects receiving methotrexate (MTX) treatment: MTX may be administered either orally or parenterally at doses not to exceed 25 mg/wk or 20 mg/m2/week (whichever is lower); participants must have taken MTX for 3 months and be at a stable dose for at least 6 weeks before baseline. Subjects taking MTX must be taking folic acid or folinic acid in accordance with local standards.

    For subjects with psoriatic arthritis, the following topical treatments for psoriasis are allowed: non medicated emollients for use over the whole body; topical steroids including hydrocortisone and hydrocortisone acetate ≤1% for the palms, soles, face, and intertriginous areas only; tar, salicylic acid preparations, and shampoos free of corticosteroids are permitted only for the scalp

  3. Inadequate response or intolerance to at least one Disease Modifying Anti Rheumatic Drug (DMARD), which may include MTX or biologic agents; in the case of ERA and psoriatic arthritis, inadequate response to Non Steroidal Anti Inflammatory Drugs (NSAIDs).
  4. No evidence or history of untreated or inadequately treated active or latent tuberculosis (TB) infection as evidenced by the following:

    1. A negative QuantiFERON ®TB Gold In Tube test performed within the 3 months prior to screening. A negative purified protein derivative (PPD) test can be substituted for the QuantiFERON® TB Gold In Tube test only if the central laboratory is unable to perform the test or cannot determine the results to be positive or negative and the Pfizer medical monitor is informed and agrees on a case by case basis.
    2. Chest radiograph without changes suggestive of active tuberculosis (TB) infection within 3 months prior to screening is recommended and should be performed according to local standards of care or country-specific guidelines.
    3. No history of either untreated or inadequately treated latent or active TB infection.

    If a subject has previously received an adequate course of therapy for either latent (9 months of isoniazid in a locale where rates of primary multi drug resistant TB infection are \<5% or an acceptable alternative regimen) or active (acceptable multi drug regimen) TB infection, neither a PPD test nor a QuantiFERON-Gold®TM test need be obtained. A chest radiograph should be obtained if not done within the 3 months prior to screening. To be considered eligible for the study, the chest radiograph must be negative for active tuberculosis infection.

    A subject who is currently being treated for latent TB infection can only be enrolled with confirmation of current incidence rates of multi-drug resistant TB infection, documentation of an adequate treatment regimen, and prior approval of the Sponsor.

  5. Fertile males and females who are, in the opinion of the investigator, sexually active and at risk for pregnancy with their partner(s) must be willing and able to use a highly effective method of as outlined in this protocol during the study and for at least 28 days after the last dose of study medication.

6 Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

  1. Evidence of a personally signed and dated document and Assent document (as appropriate) indicating that the subject and a legally acceptable representative/parent(s)/legal guardian has been informed of all pertinent aspects of the study.

Exclusion criteria

Exclusion Criteria

Subjects with any of the following characteristics/conditions will not be included in the study:

  1. Previous JIA treatment with tofacitinib.
  2. Systemic JIA (sJIA) with active systemic features (including subjects with characteristic sJIA fever and rash or serositis within 6 months of enrollment).
  3. Persistent oligoarthritis.
  4. Undifferentiated JIA.
  5. Infections:

    1. Chronic infections;
    2. Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 6 months prior to the first dose of study drug;
    3. Any treated infections within 2 weeks of Baseline visit;
    4. A subject know to be infected with (HIV), , or ;
    5. History of infected joint prosthesis with prosthesis still in situ.
  6. History of recurrent (more than one episode) herpes zoster or disseminated (at least one episode) herpes zoster, or disseminated (at least one episode) herpes simplex.
  7. Active uveitis (according to SUN criteria) within 3 months of enrollment.
  8. Blood dyscrasias, including:

    1. \<10 g/dL or Hematocrit \<33%;
    2. White Blood Cell count \<3.0 x 109/L;
    3. \<1.2 x 109/L;
    4. count \<100 x 109/L;
    5. Lymphocyte count \<0.75 x 109/L.
  9. Estimated [GFR] \<40 mL/min/1.73 m2 at Screening. GFR will be calculated by the central lab using the bedside Schwartz formula.
  10. Current or recent history of uncontrolled renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.
  11. (AST) or alanine aminotransferase (ALT) ≥1.5 times the .
  12. History of any other rheumatologic disease, other than Sjogren's syndrome..
  13. History or current symptoms suggestive of lymphoproliferative disorders (eg, Epstein Barr Virus [EBV] related lymphoproliferative disorder, lymphoma, leukemia, or signs and symptoms of current lymphatic disease).
  14. Vaccinated or exposed to a live or attenuated vaccine within the 6 weeks prior to the first dose of study drug, or is expected to be vaccinated or to have household exposure to these vaccines during treatment or during the 6 weeks following discontinuation of study drug.
  15. Subjects without documented evidence of having received at least one dose of the varicella vaccine in countries where the vaccine is approved and standard of care or those who do not have evidence of prior exposure to varicella zoster virus (VZV) based on serological testing (ie, VZV IgG Ab).
  16. Current or history of any malignancy with the exception of adequate treated or excised basal cell or squamous cell or cervical cancer in situ.
  17. Subjects who have previously failed more than 3 biologic therapies (with different mechanisms of action) for JIA.
  18. Subjects with a first degree relative with a hereditary immunodeficiency; IgA deficiency not exclusionary.
  19. Recent (within 28 days prior to first dose of study drug) significant trauma or major surgery.
  20. Subjects receiving potent and moderate inhibitors or inducers.
  21. Prior treatment with non B cell specific lymphocyte depleting agents/therapies (eg, almetuzumab [CAMPATH], alkylating agents [eg, cyclophosphamide or chlorambucil], total lymphoid irradiation, etc.). Subjects who have received rituximab or other selective B lymphocyte depleting agents (including experimental agents) are eligible if they have not received such therapy for at least 1 year prior to study baseline and have normal CD 19/20+ counts by FACS analysis.
  22. Use of prohibited prescription or non prescription drugs and dietary supplements listed in Appendix 1 and Appendix 4 within the specified time frame prior to the first dose of study medication.
  23. Herbal supplements must be discontinued at least 28 days prior to the first dose of study medication.
  24. Use of certain biologic and non biologic DMARDs are disallowed at any time during this study (Appendix 1).
  25. For subjects with PsA, oral and topical medications and alternative treatments that could affect psoriasis are prohibited (see Inclusion Criterion 2 for exceptions). This includes topical , tars, keratolytics, anthralin, vitamin D analogs, and retinoids which must be discontinued at least 2 weeks prior to first dose of study drug. Also prohibited is ultraviolet B (UVB) (narrowband or broadband) phototherapy that must be discontinued at least 2 weeks prior to first dose of study drug. Psoralens + ultraviolet A (UVA) phototherapy (PUVA) must be discontinued at least 4 weeks prior to first dose of study drug.
  26. Subjects who are children of or related to site staff members, site staff members otherwise supervised by the investigator, or Pfizer employees directly involved in the conduct of the study.
  27. Participation in other studies involving investigational drug(s) within 4 weeks or 5 half lives (whichever is longer) prior to study entry and/or during study participation. Exposure to investigational biologics should be discussed with the Sponsor.
  28. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  29. Pregnant or nursing females are excluded.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
225 participants (actual)

Study arms

  • Experimental
    CP-690,550

    Treatment arm: Tofacitinib tablets or solution, according to subjects' body weights

    Drug: CP-690,550 (tofacitinib)

  • Placebo comparator
    Placebo

    Control arm: matching placebo tablets or solution for tofacitinib

    Other: placebo

Interventions

  • During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below. During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below. Body Weight (Dosage in tablet \[BID\] or solution \[BID\]): 5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml). Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects \>=40 kg.

    Also known as: Matching placebo to tofacitinib (same tablet or solution as the active arm).

  • Otherplacebo

    matching placebo tablet or solution for tofacitinib

    Also known as: Placebo for tofacitinib

06

What researchers measure

Primary outcomes

  1. Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 44

    According to PRCSG/PRINTO, disease flare defined as worsening of \>=30 percent(%) in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range of motion accompanied by pain/tenderness), 2)Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a Visual Analog Scale\[VAS\] of 0\[no activity\] to 10\[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0\[very well\] to 10\[very poor\], 5) Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI): 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score,which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) Erythrocyte Sedimentation Rate(ESR).

    Time frame: Week 44

Secondary outcomes

  1. Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Week 44

    JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

    Time frame: Week 44

  2. Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Week 44

    JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

    Time frame: Week 44

  3. Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Week 44

    JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

    Time frame: Week 44

  4. Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Score at Week 44

    CHAQ is a valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from double-blind baseline at Week 44 in DI total score is reported.

    Time frame: Baseline, Week 44

  5. Open-Label Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 2, 4, 8, 12 and 18

    According to PRCSG/PRINTO, disease flare defined as worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

    Time frame: Weeks 2, 4, 8, 12 and 18

  6. Double Blind Phase: Percentage of Participants With Disease Flare According to PRCSG/PRINTO Disease Flare Criteria at Week 20, 24, 28, 32, 36 and 40

    According to PRCSG/PRINTO, disease flare defined as worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

    Time frame: Weeks 20, 24, 28, 32, 36 and 40

  7. Open-Label Phase: Time to Disease Flare

    Time to disease flare:time (in days) from first dose of study drug until the day of disease flare in open-label phase. According to PRCSG/PRINTO, disease flare: worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. 6 core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

    Time frame: Day 1 up to week 18

  8. Double Blind Phase: Time to Disease Flare

    Time to disease flare: time (in days) from first dose of study drug until the day of disease flare in double blind phase. According to PRCSG/PRINTO, disease flare: worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. 6 core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

    Time frame: Day 1 of Week 19 up to week 44

  9. Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Weeks 2, 4, 8, 12 and 18

    JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

    Time frame: Weeks 2, 4, 8, 12 and 18

  10. Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Double Blind Baseline, Weeks 20, 24, 28, 32, 36 and 40

    JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

    Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40

  11. Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Weeks 2, 4, 8, 12 and 18

    JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

    Time frame: Weeks 2, 4, 8, 12 and 18

  12. Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Double Blind Baseline, Weeks 20, 24, 28, 32, 36 and 40

    JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40

  13. Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Weeks 2, 4, 8, 12 and 18

    JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

    Time frame: Weeks 2, 4, 8, 12 and 18

  14. Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Double Blind Baseline (Week 18),Week 20, 24, 28, 32, 36 and 40

    JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

    Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40

  15. Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Week 2, 4, 8, 12 and 18

    JIA ACR90 response defined as: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

    Time frame: Weeks 2, 4, 8, 12 and 18

  16. Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

    JIA ACR90 response defined as: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

    Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  17. Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Week 2, 4, 8, 12 and 18

    JIA ACR100 response defined as: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

    Time frame: Weeks 2, 4, 8, 12 and 18

  18. Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

    JIA ACR100 response defined as: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

    Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  19. Open Label Phase: Change From Baseline in Juvenile Arthritis Disease Activity Score 27 (JADAS-27) C-Reactive Protein (CRP) Score at Weeks 2, 4, 8, 12 and 18

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  20. Double Blind Phase: Change From Double-Blind Baseline in Juvenile Arthritis Disease Activity Score (JADAS) 27 C-Reactive Protein (CRP) Score at Week 20, 24, 28, 32, 36, 40 and 44

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in mg/L and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  21. Open Label Phase: Change From Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Week 2, 4, 8, 12 and 18

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) ESR. The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

    Time frame: Baseline, weeks 2, 4, 8, 12 and 18

  22. Double Blind Phase: Change From Double-Blind Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Weeks 20, 24, 28, 32, 36, 40 and 44

    JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) ESR. The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  23. Open-Label Phase: Percentage of Participants With JADAS-27 CRP Minimum Disease Activity at Weeks 2, 4, 8, 12 and 18

    Minimum Disease Activity is defined by a JADAS-27 CRP score less than or equal to 3.8 for participants with polyarthritis, and less than or equal to 2 for participants with oligoarthritis. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(maximum of 27 defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

    Time frame: Weeks 2, 4, 8, 12 and 18

  24. Double Blind Phase: Percentage of Participants With JADAS-27 CRP Minimum Disease Activity at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

    Minimum Disease Activity is defined by a JADAS-27 CRP score less than or equal to 3.8 for participants with polyarthritis, and less than or equal to 2 for participants with oligoarthritis. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

    Time frame: Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

  25. Open-Label Phase: Percentage of Participants With JADAS-27 CRP Inactive Disease Activity at Week 2, 4, 8, 12 and 18

    JADAS-27 inactive disease is defined by a JADAS score less than or equal to 1. JADAS-27 Inactive Disease cutoff values are defined as: 1) Polyarthritis: Inactive Disease: \<=1 and 2) Oligoarthritis (\<4 active joints): Inactive Disease: \<=1. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

    Time frame: Weeks 2, 4, 8, 12 and 18

  26. Double Blind Phase: Percentage of Participants With JADAS-27 CRP Inactive Disease Activity at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

    JADAS-27 inactive disease is defined by a JADAS score less than or equal to 1. JADAS-27 Inactive Disease cutoff values are defined as: 1) Polyarthritis: Inactive Disease: \<=1 and 2) Oligoarthritis (\<4 active joints): Inactive Disease: \<=1. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

    Time frame: Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

  27. Double Blind Phase: Percentage of Participants With JIA ACR Inactive Disease at Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

    JIA ACR Inactive Disease criteria included: No joints with active arthritis, No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA, No active uveitis (as defined by the Standardized Uveitis Nomenclature (SUN) Working Group), Normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA, Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]) score of 'best possible' (score of "0") on the scale used, morning stiffness of \<=15 minutes.

    Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  28. Double Blind Phase: Percentage of Participants With Presence of JIA ACR Clinical Remission

    JIA ACR Clinical Remission Criteria included: Clinical inactive disease for 6 months continuously while on medications for JIA. Clinical Inactive Disease criteria included: No joints with active arthritis, No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA, No active uveitis (as defined by the SUN Working Group), Normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA, Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]) score of 'best possible' (score of "0") on the scale used, morning stiffness of less than or equal to (\<=) 15 minutes.

    Time frame: From Week 18 in double blind phase up to Week 44

  29. Open Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Active Arthritis at Week 2, 4, 8, 12 and 18

    Number of joints with active arthritis defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness. The score range of the number of joints is from 0-71.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  30. Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Number of Joints With Active Arthritis at Weeks 20, 24, 28, 32, 36, 40 and 44

    Number of joints with active arthritis defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness. Number of joints ranged from 0 to 71.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  31. Open Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Limited Range of Motion at Weeks 2, 4, 8, 12 and 18

    The maximum number of joints with limitation of movement was 67 and these were defined as those in the joint assessment with 'limitation of motion'.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  32. Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Number of Joints With Limited Range of Motion at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

    The maximum number of joints with limitation of movement was 67 and these were defined as those in the joint assessment with 'limitation of motion'.

    Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  33. Open Label Phase: JIA ACR Core Variable- Change From Baseline in Physician Global Evaluation of Disease Activity at Week 2, 4, 8, 12 and 18

    Physician global evaluation of disease activity was measured on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'No Activity' and '10' as 'Maximum Activity', higher score indicated more disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  34. Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at Weeks 20, 24, 28, 32, 36, 40 and 44

    Physician global evaluation of disease activity was measured on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'No Activity' and '10' as 'Maximum Activity', higher score indicated more disease activity.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  35. Open Label Phase: JIA ACR Core Variable- Change From Baseline in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Weeks 2, 4, 8, 12 and 18

    The parent/or legal guardian/participant rated the overall well-being on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'Very Well' and '10' as 'Very Poorly', higher scores=more disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  36. Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Weeks 20, 24, 28, 32, 36, 40 and 44

    The parent/or legal guardian/participant rated the overall well-being on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'Very Well' and '10' as 'Very Poorly', higher scores=more disease activity.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  37. Open Label Phase: JIA ACR Core Variable- Change From Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Scores at Weeks 2, 4, 8, 12 and 18

    CHAQ is a valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from baseline at Weeks 2, 4, 8, 12 and 18 in DI total score is reported.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  38. Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Scores at Weeks 20, 24, 28, 32, 36, and 40

    CHAQ: valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate overall score, participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from double-blind baseline at Weeks 20, 24, 28, 32, 36, and 40 in DI total score is reported.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, and 40

  39. Open-Label Phase: Change From Baseline in Child Health Questionnaire (CHQ) Responses at Week 4 and Week 18

    CHQ: 50-item, 14 subscale (Global health, physical functioning, social limitations: emotional, social limitations: physical, bodily pain, behavior, global behavior, mental health, self-esteem, general health, Change in health, emotional impact on parent, time impact on parent, family activities, family cohesion) parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents. Each subscale rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Two summary scores: Physical Health and Psychosocial Health were weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.

    Time frame: Baseline, Week 4 and Week 18

  40. Double Blind Phase: Change From Double-Blind Baseline in Child Health Questionnaire (CHQ) Responses at Week 44

    CHQ: 50-item, 14 subscale (Global health, physical functioning, social limitations: emotional, social limitations: physical, bodily pain, behavior, global behavior, mental health, self-esteem, general health, Change in health, emotional impact on parent, time impact on parent, family activities, family cohesion) parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents. Each subscale rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Two summary scores: Physical Health and Psychosocial Health were weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.

    Time frame: Double-Blind Baseline (Week 18), Week 44

  41. Open Label Phase: Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Weeks 2, 4, 8, 12 and 18

    CHAQ is a validated instrument and comprises of two indices, Disability and Discomfort, and global assessment of arthritis (overall well-being). Discomfort Index included: assessment of discomfort, the parent/legal guardian/participant were asked to provide a response to the question: How much pain do you think your child had because of his or her illness in the past week?, The parent/legal guardian/ participant rated the overall pain on a 0 to 10 VAS, where '0' indicates 'No Pain' and '10' indicates 'Very Severe Pain', higher scores indicates more severity.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  42. Double Blind Phase:Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Weeks 20, 24, 28, 32, 36, 40 and 44

    CHAQ is a validated instrument and comprises of two indices, Disability and Discomfort, and global assessment of arthritis (overall well-being). Discomfort Index included: assessment of discomfort, the parent/legal guardian/participant were asked to provide a response to the question: How much pain do you think your child had because of his or her illness in the past week?, The parent/legal guardian/ participant rated the overall pain on a 0 to 10 VAS, where '0' indicates 'No Pain' and '10' indicates 'Very Severe Pain', higher scores indicates more severity.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36,40 and 44

  43. Open-Label Phase: Percentage of Participants With Active Uveitis at Baseline

    Uveitis is the inflammation of the uvea. Participants were assessed for presence of uveitis (according to Standard Uveitis Nomenclature \[SUN\]). If Uveitis was present in participant at Baseline, it was considered as "active uveitis"; If Uveitis was not present in participant at Baseline, it was considered as "Inactive uveitis". As per SUN, Uveitis is defined as: anterior (in which anterior chamber is primary site of inflammation); intermediate (primary site of inflammation: vitreous); posterior (primary site of inflammation: retina or choroid). Percentage of participants with active uveitis (of any type) are reported.

    Time frame: Baseline

  44. Double Blind Phase: Percentage of Participants With Active Uveitis at Week 24 and Week 44

    Uveitis is the inflammation of the uvea. Participants were assessed for presence of uveitis (according to Standard Uveitis Nomenclature \[SUN\]). If Uveitis was present in participant at Baseline, it was considered as "active uveitis"; If Uveitis was not present in participant at Baseline, it was considered as "Inactive uveitis". As per SUN, Uveitis is defined as: anterior (in which anterior chamber is primary site of inflammation); intermediate (primary site of inflammation: vitreous); posterior (primary site of inflammation: retina or choroid). Percentage of participants with active uveitis (of any type) are reported.

    Time frame: Week 24 and Week 44

  45. Open-Label Phase: Change From Baseline in the Tender Entheseal Assessment at Weeks 2, 4, 8, 12 and 18

    Participants with enthesitis-related arthritis (ERA) undergo Tender entheseal assessment. Tender entheseal assessment: Entheses were assessed and coded as: 1= any tenderness, 0= no tenderness, NE= not evaluable. Total number of tender entheses: 66\*(total number of tender entheses with counts \> 0)/number of non-missing tender entheses. If \> 33 tender entheseal counts were missing, total number of tender entheses was defined as missing.

    Time frame: Baseline, weeks 2, 4, 8, 12 and 18

  46. Double Blind Phase: Change From Double-Blind Baseline in the Tender Entheseal Assessment at Weeks 20, 24, 28, 32, 36, 40 and 44

    Participants with ERA undergo Tender entheseal assessment. Tender entheseal assessment: Entheses were assessed and coded as: 1= any tenderness, 0= no tenderness, NE= not evaluable. Total number of tender entheses: 66\*(total number of tender entheses with counts \> 0)/number of non-missing tender entheses. If \> 33 tender entheseal counts were missing, total number of tender entheses was defined as missing.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  47. Open-Label Phase: Change From Baseline in the Modified Schober's Test at Week 2, 4, 8, 12 and 18

    Participants with ERA undergo Modified Schober's Test. In the Modified Schober's Test, a mark was placed 5 cm below the midpoint of a line that joined the posterior superior iliac spines. Another mark was placed 10 cm above the first. The participant then bent maximally forward with the knees fully extended. The distance between the two marks was then re-measured. The full measurement between the two lines was recorded to the nearest tenth of a centimeter and is reported.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  48. Double Blind Phase: Change From Double Blind Baseline in the Modified Schober's Test at Week 20, 24, 28, 32, 36, 40 and 44

    Participants with ERA undergo Modified Schober's Test. In the Modified Schober's Test, a mark was placed 5 cm below the midpoint of a line that joined the posterior superior iliac spines. Another mark was placed 10 cm above the first. The participant then bent maximally forward with the knees fully extended. The distance between the two marks was then re-measured. The full measurement between the two lines was recorded to the nearest tenth of a centimeter and is reported.

    Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  49. Open-Label Phase: Change From Baseline in the Overall Back Pain and Nocturnal Back Pain Responses at Week 2, 4, 8, 12 and 18

    Participants with ERA undergo Overall Back Pain and Nocturnal Back Pain assessment. For Overall Back Pain, parent/legal guardian/participant were asked to provide a response to the question: What is the amount of back pain at any time that your child experienced in the past week? And For Nocturnal Back Pain: What is the amount of back pain at night that your child experienced in the past week?. Response to these questions was provided by parent/legal guardian/participant using a VAS of 0-10, where 0= No Pain and 10= Most Severe Pain, higher score indicated more severe pain.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  50. Double Blind Phase: Change From Double-Blind Baseline in the Overall Back Pain and Nocturnal Back Pain Responses at Week 20, 24, 28, 32, 36, 40 and 44

    Participants with ERA undergo Overall Back Pain and Nocturnal Back Pain assessment. For Overall Back Pain, parent/legal guardian/participant were asked to provide a response to the question: What is the amount of back pain at any time that your child experienced in the past week? And For Nocturnal Back Pain: What is the amount of back pain at night that your child experienced in the past week?. Response to these questions was provided by parent/legal guardian/participant using a VAS of 0-10, where 0= No Pain and 10= Most Severe Pain, higher score indicated more severe pain.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  51. Open-Label Phase: Changes From Baseline in Percentage of Body Surface Area (BSA) Affected With Psoriasis at Weeks 2, 4, 8, 12 and 18

    Percentage of body surface area affected by psoriasis was estimated using the palm method. One of the participant's palm to proximal interphalangeal (PIP) and thumb =\\together represented 1% of total BSA. Regions of the body were assigned specific number of palms with percentage (Head and Neck = 10% \[10 palms\], Upper extremities = 20% \[20 palms\], Trunk \[axillae and groin\] = 30% \[30 palms\], Lower extremities \[buttocks\] = 40% \[40 palms\]). The number of palms of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  52. Double Blind Phase: Changes From Double Blind Baseline in Body Surface Area (BSA) Affected With Psoriasis at Week 20, 24, 28, 32, 36, 40 and 44

    Percentage of body surface area affected by psoriasis was estimated using the palm method. One of the participant's palm to PIP and thumb together represented 1% of total BSA. Regions of the body were assigned specific number of palms with percentage (Head and Neck = 10% \[10 palms\], Upper extremities = 20% \[20 palms\], Trunk \[axillae and groin\] = 30% \[30 palms\], Lower extremities \[buttocks\] = 40% \[40 palms\]). The number of palms of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

    Time frame: Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  53. Open-Label Phase: Changes From Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Weeks 2, 4, 8, 12 and 18

    The PGA of psoriasis was scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 5 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and ranged as 0= no symptom to 5=severe, higher score indicates more severity.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  54. Double Blind Phase:Change From Double-Blind Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Weeks 20, 24, 28, 32, 36, 40 and 44

    The PGA of psoriasis was scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 5 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and ranged as 0= no symptom to 5=severe, higher score indicates more severity.

    Time frame: Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

  55. Open-Label Phase: Taste Assessment of Tofacitinib Oral Solution on Day 14

    Oral solution was given only to participants weighing \<40 kg and to the participants who were unable to swallow tablets. Taste assessment was evaluated using a 5 categories questionnaire. Participants were asked to answer in one of the following categories to describe the taste of oral solution of tofacitinib: dislike very much, dislike a little, not sure, like a little and like very much. Number of participants within each category are reported.

    Time frame: Day 14

  56. Open-Label Phase: Number of Participants With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases

    Serious infection defined as any infection that requires hospitalization for treatment or requires parenteral antimicrobial therapy or meets other criteria that require it to be classified as a serious adverse event. Cytopenia was categorized as: lymphocyte counts: \<500 lymphocytes/ millimeter\^3 (mm), neutrophil counts \<1000 neutrophils/mm\^3, platelet counts \<100,000 platelets/mm\^3, any single hemoglobin value \<8 grams/decilitre (g/dL) and any single hemoglobin value drops \>=2 g/dL below baseline. Number of Participants With serious infections, cytopenia, malignancies and Cardiovascular Diseases are reported.

    Time frame: From the first dose of study drug up to Week 18

  57. Double Blind Phase: Number of Participants With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases

    Serious infection defined as any infection that requires hospitalization for treatment or requires parenteral antimicrobial therapy or meets other criteria that require it to be classified as a serious adverse event. Cytopenia was categorized as: lymphocyte counts \<500 lymphocytes/mm\^3, neutrophil counts \<1000 neutrophils/mm\^3, platelet counts \<100000 platelets/mm\^3, any single hemoglobin (hg) value \<8 g/dL and any single hemoglobin value drops \>=2 g/dL below baseline. Number of Participants With serious infections, cytopenia, malignancies and Cardiovascular Diseases are reported.

    Time frame: From the first dose of study drug in double blind up to week 44

  58. Open-Label Phase: Number of Participants With Tanner Staging Evaluation (Pubic Hair)

    Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: no hair, Stage 2: downy hair, Stage 3: Scant terminal hair, Stage 4: Terminal hair that fills the entire triangle overlying the pubic region and Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh. Tanner Stage for pubic hair at Day 1 was summarized and reported using number of participants in each stage.

    Time frame: Day 1

  59. Double Blind Phase: Number of Participants With Tanner Staging Evaluation (Pubic Hair)

    Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males) were assessed in this study and with values in the scale ranging from: Stage 1: no hair, Stage 2: downy hair, Stage 3: Scant terminal hair, Stage 4: Terminal hair that fills the entire triangle overlying the pubic region and Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh. Tanner Stage for pubic hair at Week 44 was summarized and reported using number of participants in each stage.

    Time frame: Week 44

  60. Open-Label Phase: Number of Participants With Tanner Staging Evaluation (Breast Exam)

    Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: No glandular breast tissue palpable, Stage 2: Breast bud palpable under areola (1st pubertal sign in females), Stage 3: Breast tissue palpable outside areola; no areolar development, Stage 4: Areola elevated above contour of the breast, forming "double scoop" appearance, Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion. Tanner Stage for Breast at Day 1 was summarized and reported using number of participants in each stage.

    Time frame: Day 1

  61. Double Blind Phase: Number of Participants With Tanner Staging Evaluation (Breast Exam)

    Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: No glandular breast tissue palpable, Stage 2: Breast bud palpable under areola (1st pubertal sign in females), Stage 3: Breast tissue palpable outside areola; no areolar development, Stage 4: Areola elevated above contour of the breast, forming "double scoop" appearance, Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion. Tanner Stage for Breast at Week 44 was summarized and reported using number of participants in each stage.

    Time frame: Week 44

  62. Open-Label Phase: Number of Participants With Tanner Staging Evaluation (Genitalia)

    Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: Testicular volume \< 4 ml or long axis \< 2.5 cm, Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males, Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long), Stage 4: 15-20 ml (or 4.1-4.5 cm long), Stage 5: \> 20 ml (or \> 4.5 cm long). Tanner Stage for genitalia at Day 1 was summarized and reported using number of participants in each stage.

    Time frame: Day 1

  63. Double Blind Phase: Number of Participants With Tanner Staging Evaluation (Genitalia)

    Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: Testicular volume \< 4 ml or long axis \< 2.5 cm, Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males, Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long), Stage 4: 15-20 ml (or 4.1-4.5 cm long), Stage 5: \> 20 ml (or \> 4.5 cm long). Tanner Stage for genitalia at Week 44 was summarized and reported using number of participants in each stage.

    Time frame: Week 44

  64. Open-Label Phase: Number of Participants With Laboratory Abnormalities

    Criteria: Hemoglobin(Hg),hematocrit erythrocytes(Ery); \<0.8\*lower limit of normal (LLN), Ery. Mean Corpuscular Volume; \<0.9\*LLN, \>1.1\*upper limit of normal (ULN), Platelets; \<0.5\*LLN, \>1.75\*ULN, Leukocytes (leu); \<0.6\*LLN, \>1.5\*ULN, Lymphocytes (Ly), Ly/leu, Neutrophils, Neutrophils/leu \<0.8\*LLN, Basophils/leu, Eosinophils, Eosinophils/leu, Monocytes, Monocytes/leu \>1.2\*ULN, Ery Sedimentation Rate \>1.5\*ULN. Bilirubin, Indirect Bilirubin \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase, Alkaline Phosphatase \>3.0\*ULN, Albumin \>1.2\*ULN, Creatinine \>1.3\*ULN, HDL Cholesterol (Chol)\<0.8\*LLN, LDL Chol, LDL Chol Friedewald Est PEG \>1.2\*ULN, Triglycerides \>1.3\*ULN, Calcium \<0.9\*LLN, Bicarbonate \<0.9\*LLN, Glucose \>1.5\*ULN, Creatine Kinase \>2.0\*ULN, C Reactive Protein \>1.1\*ULN, Chol \>1.3\*ULN. Urinalysis: Specific Gravity \>1.030, Glucose, Ketones, Protein, Hg, Nitrite, Leu Esterase \>=1, Ery, Leu \>=20, Hyaline Casts \>1.Only those category in which at least 1 participant had data is reported.

    Time frame: From the first dose of study drug up to Week 18

  65. Double Blind Phase: Number of Participants With Laboratory Abnormalities

    Criteria: Hg, hematocrit Ery; \<0.8\* LLN, Ery. Mean Corpuscular Volume; \<0.9\*LLN, \>1.1\* ULN, Platelets; \<0.5\*LLN, \>1.75\*ULN, leu; \<0.6\*LLN, \>1.5\*ULN, Ly, Ly/leu, Neutrophils, Neutrophils/leu \<0.8\*LLN, Basophils/leu, Eosinophils, Eosinophils/leu, Monocytes, Monocytes/leu \>1.2\*ULN, Prothrombin Time \>1.1\*ULN, Ery Sedimentation Rate \>1.5\*ULN. Bilirubin, Direct Bilirubin, Indirect Bilirubin \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase (GGT), Alkaline Phosphatase \>3.0\*ULN, Albumin \>1.2\*ULN, Creatinine \>1.3\*ULN, HDL Cholesterol (Chol)\<0.8\*LLN, LDL Chol, LDL Chol Friedewald Est PEG \>1.2\*ULN, Triglycerides \>1.3\*ULN, Calcium \<0.9\*LLN, Bicarbonate \<0.9\*LLN, Glucose \>1.5\*ULN, Creatine Kinase \>2.0\*ULN, C Reactive Protein \>1.1\*ULN, Chol \>1.3\*ULN. Urinalysis: Specific Gravity \>1.030, pH \>8, urine Glucose, Ketones, Protein, Hg, Nitrite, Leu Esterase \>=1, Ery, Leu \>=20, Hyaline Casts \>1.Only those category in which at least 1 participant had data is reported.

    Time frame: From the first dose of study drug in double blind up to Week 44

  66. Open-Label Phase: Number of Participants With Physical Examination Abnormalities

    Physical examination included: abdomen, ears, extremities, eyes, general appearance, head, heart, lungs, lymph nodes, neurological, nose, skin, and throat. Abnormality in physical examination was based on investigator's discretion.

    Time frame: Baseline, Weeks 2, 4, 8, 12 and 18

  67. Double Blind Phase: Number of Participants With Physical Examination Abnormalities

    Physical examination included: abdomen, ears, extremities, eyes, general appearance, head, heart, lungs, lymph nodes, neurological, nose, skin, and throat. Abnormality in physical examination was based on investigator's discretion.

    Time frame: Weeks 18, 20, 24, 28, 32, 36, 40 and 44

  68. Open-Label Phase: Number of Participants With Vital Sign Abnormalities

    Vital Sign Abnormalities criteria included: sitting diastolic blood pressure millimeters of Mercury (mmHG) of \<50 mmHg, sitting pulse rate beats per minute (bpm) of \<40 or 120 bpm, sitting systolic blood pressure (mmHG) of \<90 mmHg, supine diastolic blood pressure (mmHG) of \<50 mmHg, supine pulse rate (BPM) of \<40 bpm or \>120 bpm, supine systolic blood pressure (mmHG) of 90 mmHg.

    Time frame: From the first dose of study drug up to Week 18

  69. Double Blind Phase: Number of Participants With Vital Sign Abnormalities

    Vital Sign Abnormalities criteria included: diastolic blood pressure (mmHG) of \<50 mmHg, Pulse rate (BPM) of \<40 bpm or \>120 bpm, sitting diastolic blood pressure (mmHG) of \<50 mmHg, sitting pulse rate beats per minute (bpm) of \<40 bpm or \>120 bpm, sitting systolic blood pressure (mmHG) of \<90 mmHg, supine diastolic blood pressure (mmHG) of \<50 mmHg, supine pulse rate (BPM) of \<40 bpm or \>120 bpm, supine systolic blood pressure (mmHG) of \<90 mmHg, systolic blood pressure (mmHG) of \<90 mmHg.

    Time frame: From the first dose of study drug in double blind up to week 44

  70. Open-Label Phase: Number of Participants With Change From Baseline in Vital Sign Measures

    Change in vital Signs included: Sitting diastolic blood pressure \[mmHG\]: \>=20mmHg increase from baseline (IFB) and \>= 20mmHg decrease from baseline (DFB). Sitting systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB. Supine diastolic blood pressure mmHG: \>= 20mmHg IFB and \>= 20mmHg DFB. Supine systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB.

    Time frame: From the first dose of study drug up to Week 18

  71. Double Blind Phase: Number of Participants With Change From Baseline in Vital Sign Measures

    Change in vital Signs included: Sitting diastolic blood pressure (mmHG): \>=20mmHg IFB and \>= 20mmHg DFB. Sitting systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB. Supine diastolic blood pressure mmHG: \>= 20mmHg IFB and \>= 20mmHg DFB. Supine systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB.

    Time frame: From the first dose of study drug in double blind up to week 44

07

Results

Posted Feb 21, 2020
Limitations and caveats
Data not reported for the PK endpoints, since the PK dataset will be combined together with PK data from other studies and analyze in a pooled analysis; the results of this pooled analysis will be reported separately.

Participant flow

Open-Label Phase (18 Weeks)
Participant flow — Open-Label Phase (18 Weeks)
MilestoneTofacitinib: Open-Label PhaseTofacitinib: Double Blind PhasePlacebo
Started22500
Treated22500
Completed18500
Not completed4000
Withdrew: Adverse event1200
Withdrew: Insufficient clinical response2100
Withdrew: Other300
Withdrew: Protocol deviation400
Double Blind Phase (26 Weeks)
Participant flow — Double Blind Phase (26 Weeks)
MilestoneTofacitinib: Open-Label PhaseTofacitinib: Double Blind PhasePlacebo
Started08885
Treated08885
Completed06138
Not completed02747
Withdrew: Adverse event022
Withdrew: Insufficient clinical response02244
Withdrew: Other010
Withdrew: Protocol deviation001
Withdrew: Medication error without associated aes010
Withdrew: Withdrawal by parent/guardian010

Outcome measures

PrimaryDouble Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 44

According to PRCSG/PRINTO, disease flare defined as worsening of \>=30 percent(%) in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables: 1) Number of joints with active arthritis (joint with swelling/in absence of swelling, limited range of motion accompanied by pain/tenderness), 2)Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a Visual Analog Scale\[VAS\] of 0\[no activity\] to 10\[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0\[very well\] to 10\[very poor\], 5) Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI): 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score,which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) Erythrocyte Sedimentation Rate(ESR).

Time frame:
Week 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 44
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 4429.1752.86
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0031 (Threshold for significance at 0.05 level.) · Difference in percentage: -23.69 · 95% CI -39.41 to -7.97
SecondaryDouble Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Week 44

JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

Time frame:
Week 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Week 44
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Week 4466.6747.14
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0166 (Threshold for significance at 0.05 level.) · Difference in percentage: 19.52 · 95% CI 3.55 to 35.50
SecondaryDouble Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Week 44

JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

Time frame:
Week 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Week 44
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Week 4470.8347.14
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0031 (Threshold for significance at 0.05 level.) · Difference in percentage: 23.69 · 95% CI 7.97 to 39.41
SecondaryDouble Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Week 44

JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

Time frame:
Week 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Week 44
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Week 4454.1737.14
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0387 (Threshold for significance at 0.05 level.) · Difference in percentage: 17.02 · 95% CI 0.88 to 33.17
SecondaryDouble Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Score at Week 44

CHAQ is a valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from double-blind baseline at Week 44 in DI total score is reported.

Time frame:
Baseline, Week 44
Reported as:
Least squares mean · units on a scale
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Score at Week 44
units on a scaleTofacitinib: Double Blind PhasePlacebo
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Score at Week 44-0.09 ± 0.040.03 ± 0.04
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Mixed Model for Repeated Measures (MMRM) · p = 0.0292 (Threshold for significance at 0.05 level.) · Ls mean difference: -0.12 · 95% CI -0.22 to -0.01
SecondaryOpen-Label Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 2, 4, 8, 12 and 18

According to PRCSG/PRINTO, disease flare defined as worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

Time frame:
Weeks 2, 4, 8, 12 and 18
Reported as:
Number · percentage of participants
Open-Label Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International Trials Organization (PRCSG/PRINTO) Disease Flare Criteria at Week 2, 4, 8, 12 and 18
percentage of participantsTofacitinib: Open-Label Phase
Week 20.54
Week 43.83
Week 85.14
Week 127.23
Week 188.44
SecondaryDouble Blind Phase: Percentage of Participants With Disease Flare According to PRCSG/PRINTO Disease Flare Criteria at Week 20, 24, 28, 32, 36 and 40

According to PRCSG/PRINTO, disease flare defined as worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. Six core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

Time frame:
Weeks 20, 24, 28, 32, 36 and 40
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Disease Flare According to PRCSG/PRINTO Disease Flare Criteria at Week 20, 24, 28, 32, 36 and 40
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Week 209.7211.43
Week 2412.5031.43
Week 2818.0637.14
Week 3223.6145.71
Week 3625.0048.57
Week 4027.7852.86
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.7410 · Difference in percentage: -1.71 · 95% CI -11.82 to 8.41
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0052 · Difference in percentage: -18.93 · 95% CI -32.22 to -5.64
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0093 · Difference in percentage: -19.09 · 95% CI -33.48 to -4.70
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0045 · Difference in percentage: -22.10 · 95% CI -37.35 to -6.86
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0027 · Difference in percentage: -23.57 · 95% CI -38.97 to -8.17
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0016 · Difference in percentage: -25.08 · 95% CI -40.69 to -9.47
SecondaryOpen-Label Phase: Time to Disease Flare

Time to disease flare:time (in days) from first dose of study drug until the day of disease flare in open-label phase. According to PRCSG/PRINTO, disease flare: worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. 6 core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

Time frame:
Day 1 up to week 18
Reported as:
Median · days
Open-Label Phase: Time to Disease Flare
daysTofacitinib: Open-Label Phase
Open-Label Phase: Time to Disease FlareNA (NA to NA)
SecondaryDouble Blind Phase: Time to Disease Flare

Time to disease flare: time (in days) from first dose of study drug until the day of disease flare in double blind phase. According to PRCSG/PRINTO, disease flare: worsening of \>=30% in \>=3 of 6 variables of JIA core set, with no more than 1 variable improving by \>=30%. 6 core variables were: 1) Number of joints with active arthritis (joint with swelling or in absence of swelling, limited range of motion accompanied by pain/ tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

Time frame:
Day 1 of Week 19 up to week 44
Reported as:
Median · days
Double Blind Phase: Time to Disease Flare
daysTofacitinib: Double Blind PhasePlacebo
Double Blind Phase: Time to Disease FlareNA (NA to NA)155.0 (86.0 to NA)
SecondaryOpen-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Weeks 2, 4, 8, 12 and 18

JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

Time frame:
Weeks 2, 4, 8, 12 and 18
Reported as:
Number · percentage of participants
Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Weeks 2, 4, 8, 12 and 18
percentage of participantsTofacitinib: Open-Label Phase
Week 245.11
Week 468.31
Week 879.66
Week 1285.63
Week 1892.21
SecondaryDouble Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Double Blind Baseline, Weeks 20, 24, 28, 32, 36 and 40

JIA ACR30 response defined as: \>=30% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

Time frame:
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 Response at Double Blind Baseline, Weeks 20, 24, 28, 32, 36 and 40
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Baseline (Week 18)100.00100.00
Week 2088.8982.86
Week 2486.1168.57
Week 2880.5661.43
Week 3276.3952.86
Week 3673.6148.57
Week 4070.8347.14
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.3010 · Difference in percentage: 6.03 · 95% CI -5.40 to 17.46
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0108 · Difference in percentage: 17.54 · 95% CI 4.05 to 31.03
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0103 · Difference in percentage: 19.13 · 95% CI 4.51 to 33.74
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0025 · Difference in percentage: 23.53 · 95% CI 8.27 to 38.80
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0016 · Difference in percentage: 25.04 · 95% CI 9.52 to 40.56
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0031 · Difference in percentage: 23.69 · 95% CI 7.97 to 39.41
SecondaryOpen-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Weeks 2, 4, 8, 12 and 18

JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

Time frame:
Weeks 2, 4, 8, 12 and 18
Reported as:
Number · percentage of participants
Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Weeks 2, 4, 8, 12 and 18
percentage of participantsTofacitinib: Open-Label Phase
Week 220.11
Week 444.81
Week 862.71
Week 1271.86
Week 1883.77
SecondaryDouble Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Double Blind Baseline, Weeks 20, 24, 28, 32, 36 and 40

JIA ACR50 response defined as: \>=50% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 50 Response at Double Blind Baseline, Weeks 20, 24, 28, 32, 36 and 40
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Baseline (Week 18)90.2891.43
Week 2081.9474.29
Week 2480.5658.57
Week 2873.6155.71
Week 3269.4444.29
Week 3668.0647.14
Week 4068.0645.71
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation for binomial · p = 0.8119 · Difference in percentage: -1.15 · 95% CI -10.63 to 8.33
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation for binomial · p = 0.2682 · Difference in percentage: 7.66 · 95% CI -5.90 to 21.21
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation for binomial · p = 0.0034 · Difference in percentage: 21.98 · 95% CI 7.26 to 36.71
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation for binomial · p = 0.0233 · Difference in percentage: 17.90 · 95% CI 2.44 to 33.36
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation for binomial · p = 0.0018 · Difference in percentage: 25.16 · 95% CI 9.39 to 40.93
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation for binomial · p = 0.0099 · Difference in percentage: 20.91 · 95% CI 5.01 to 36.81
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation for binomial · p = 0.0058 · Difference in percentage: 22.34 · 95% CI 6.46 to 38.22
SecondaryOpen-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Weeks 2, 4, 8, 12 and 18

JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

Time frame:
Weeks 2, 4, 8, 12 and 18
Reported as:
Number · percentage of participants
Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Weeks 2, 4, 8, 12 and 18
percentage of participantsTofacitinib: Open-Label Phase
Week 27.61
Week 416.94
Week 836.16
Week 1246.71
Week 1861.04
SecondaryDouble Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Double Blind Baseline (Week 18),Week 20, 24, 28, 32, 36 and 40

JIA ACR70 response defined as: \>=70% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

Time frame:
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36 and 40
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 70 Response at Double Blind Baseline (Week 18),Week 20, 24, 28, 32, 36 and 40
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Baseline (Week 18)68.0664.29
Week 2058.3355.71
Week 2458.3344.29
Week 2854.1747.14
Week 3256.9438.57
Week 3654.1734.29
Week 4054.1734.29
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.6348 · Difference in percentage: 3.77 · 95% CI -11.79 to 19.33
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.7525 · Difference in percentage: 2.62 · 95% CI -13.66 to 18.90
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0908 · Difference in percentage: 14.05 · 95% CI -2.23 to 30.33
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.4026 · Difference in percentage: 7.02 · 95% CI -9.38 to 23.43
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0258 · Difference in percentage: 18.37 · 95% CI 2.22 to 34.52
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0149 · Difference in percentage: 19.88 · 95% CI 3.88 to 35.88
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0149 · Difference in percentage: 19.88 · 95% CI 3.88 to 35.88
SecondaryOpen-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Week 2, 4, 8, 12 and 18

JIA ACR90 response defined as: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction); 6) ESR.

Time frame:
Weeks 2, 4, 8, 12 and 18
Reported as:
Number · percentage of participants
Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Week 2, 4, 8, 12 and 18
percentage of participantsTofacitinib: Open-Label Phase
Week 20
Week 43.83
Week 811.30
Week 1220.96
Week 1833.12
SecondaryDouble Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

JIA ACR90 response defined as: \>=90% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

Time frame:
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 90 Response at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Baseline (Week 18)33.3338.57
Week 2034.7225.71
Week 2437.5028.57
Week 2836.1127.14
Week 3238.8922.86
Week 3638.8920.00
Week 4034.7222.86
Week 4434.7221.43
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.5150 · Difference in percentage: -5.24 · 95% CI -21.00 to 10.53
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.2400 · Difference in percentage: 9.01 · 95% CI -6.02 to 24.03
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.2557 · Difference in percentage: 8.93 · 95% CI -6.47 to 24.33
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.2481 · Difference in percentage: 8.97 · 95% CI -6.25 to 24.19
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0356 · Difference in percentage: 16.03 · 95% CI 1.08 to 30.98
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0115 · Difference in percentage: 18.89 · 95% CI 4.24 to 33.54
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.1150 · Difference in percentage: 11.87 · 95% CI -2.89 to 26.62
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0744 · Difference in percentage: 13.29 · 95% CI -1.31 to 27.90
SecondaryOpen-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Week 2, 4, 8, 12 and 18

JIA ACR100 response defined as: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

Time frame:
Weeks 2, 4, 8, 12 and 18
Reported as:
Number · percentage of participants
Open-Label Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Week 2, 4, 8, 12 and 18
percentage of participantsTofacitinib: Open-Label Phase
Week 20.0
Week 42.19
Week 88.47
Week 1214.37
Week 1821.43
SecondaryDouble Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

JIA ACR100 response defined as: \>=100% improvement in 3 out of 6 JIA core set variables with no more than 1 out of 6 JIA core set variables worsened by \>=30%. Six core variables: 1) Number of joints with active arthritis (defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 2) Number of joints with limited range of motion, 3) Physician global evaluation of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 4) Parent/legal guardian/participant global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\], 5) CHAQ-DI: 30 questions in 8 domains, each question answered on scale of 0=without difficulty to 3=unable to do; scores of each domain were averaged to derive total CHAQ-DI score, which ranges from 0 (minimum dysfunction) to 3 (most severe dysfunction);6) ESR.

Time frame:
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 100 Response at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Baseline (Week 18)15.2831.43
Week 2027.7817.14
Week 2427.7824.29
Week 2826.3924.29
Week 3227.7821.43
Week 3630.5618.57
Week 4029.1720.00
Week 4429.1717.14
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0207 · Difference in percentage: -16.15 · 95% CI -29.84 to -2.46
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.1254 · Difference in percentage: 10.63 · 95% CI -2.97 to 24.24
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.6350 · Difference in percentage: 3.49 · 95% CI -10.93 to 17.91
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.7732 · Difference in percentage: 2.10 · 95% CI -12.20 to 16.41
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.3782 · Difference in percentage: 6.35 · 95% CI -7.77 to 20.47
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0936 · Difference in percentage: 11.98 · 95% CI -2.02 to 25.99
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.2017 · Difference in percentage: 9.17 · 95% CI -4.91 to 23.24
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0858 · Difference in percentage: 12.02 · 95% CI -1.69 to 25.74
SecondaryOpen Label Phase: Change From Baseline in Juvenile Arthritis Disease Activity Score 27 (JADAS-27) C-Reactive Protein (CRP) Score at Weeks 2, 4, 8, 12 and 18

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · score on scale
Open Label Phase: Change From Baseline in Juvenile Arthritis Disease Activity Score 27 (JADAS-27) C-Reactive Protein (CRP) Score at Weeks 2, 4, 8, 12 and 18
score on scaleTofacitinib: Open-Label Phase
Week 2-6.35 ± 5.44
Week 4-9.89 ± 6.54
Week 8-12.47 ± 7.51
Week 12-14.33 ± 6.96
Week 18-15.80 ± 7.12
SecondaryDouble Blind Phase: Change From Double-Blind Baseline in Juvenile Arthritis Disease Activity Score (JADAS) 27 C-Reactive Protein (CRP) Score at Week 20, 24, 28, 32, 36, 40 and 44

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in mg/L and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Least squares mean · score on scale
Double Blind Phase: Change From Double-Blind Baseline in Juvenile Arthritis Disease Activity Score (JADAS) 27 C-Reactive Protein (CRP) Score at Week 20, 24, 28, 32, 36, 40 and 44
score on scaleTofacitinib: Double Blind PhasePlacebo
Week 200.27 ± 0.642.33 ± 0.64
Week 240.83 ± 0.954.46 ± 0.97
Week 280.51 ± 0.914.36 ± 0.97
Week 320.16 ± 0.733.46 ± 0.81
Week 360.34 ± 1.096.55 ± 1.22
Week 400.85 ± 1.137.11 ± 1.26
Week 440.03 ± 0.914.39 ± 1.00
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0088 · Ls mean difference: -2.07 · 95% CI -3.60 to -0.53
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0054 · Ls mean difference: -3.64 · 95% CI -6.17 to -1.10
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0039 · Ls mean difference: -3.85 · 95% CI -6.38 to -1.32
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0022 · Ls mean difference: -3.30 · 95% CI -5.30 to -1.29
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0005 · Ls mean difference: -6.21 · 95% CI -9.42 to -3.00
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0006 · Ls mean difference: -6.26 · 95% CI -9.60 to -2.92
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0027 · Ls mean difference: -4.36 · 95% CI -7.02 to -1.71
SecondaryOpen Label Phase: Change From Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Week 2, 4, 8, 12 and 18

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) ESR. The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

Time frame:
Baseline, weeks 2, 4, 8, 12 and 18
Reported as:
Mean · score on scale
Open Label Phase: Change From Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Week 2, 4, 8, 12 and 18
score on scaleTofacitinib: Open-Label Phase
Week 2-6.38 ± 5.52
Week 4-10.14 ± 6.63
Week 8-12.60 ± 7.60
Week 12-14.54 ± 6.90
Week 18-15.94 ± 7.17
SecondaryDouble Blind Phase: Change From Double-Blind Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Weeks 20, 24, 28, 32, 36, 40 and 44

JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 ESR score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) ESR. The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Least squares mean · score on scale
Double Blind Phase: Change From Double-Blind Baseline in JADAS-27 Erythrocyte Sedimentation Rate (ESR) Score at Weeks 20, 24, 28, 32, 36, 40 and 44
score on scaleTofacitinib: Double Blind PhasePlacebo
Week 200.62 ± 0.622.45 ± 0.62
Week 240.92 ± 0.904.33 ± 0.92
Week 280.64 ± 0.864.22 ± 0.90
Week 320.26 ± 0.753.67 ± 0.81
Week 360.60 ± 1.066.26 ± 1.17
Week 400.73 ± 1.056.35 ± 1.15
Week 440.09 ± 0.914.50 ± 0.97
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0172 · Ls mean difference: -1.83 · 95% CI -3.32 to -0.33
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0057 · Ls mean difference: -3.41 · 95% CI -5.81 to -1.01
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0038 · Ls mean difference: -3.58 · 95% CI -5.94 to -1.23
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0020 · Ls mean difference: -3.41 · 95% CI -5.47 to -1.36
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0007 · Ls mean difference: -5.66 · 95% CI -8.74 to -2.57
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0007 · Ls mean difference: -5.62 · 95% CI -8.66 to -2.58
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0018 · Ls mean difference: -4.41 · 95% CI -6.99 to -1.82
SecondaryOpen-Label Phase: Percentage of Participants With JADAS-27 CRP Minimum Disease Activity at Weeks 2, 4, 8, 12 and 18

Minimum Disease Activity is defined by a JADAS-27 CRP score less than or equal to 3.8 for participants with polyarthritis, and less than or equal to 2 for participants with oligoarthritis. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease(maximum of 27 defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

Time frame:
Weeks 2, 4, 8, 12 and 18
Reported as:
Number · percentage of participants
Open-Label Phase: Percentage of Participants With JADAS-27 CRP Minimum Disease Activity at Weeks 2, 4, 8, 12 and 18
percentage of participantsTofacitinib: Open-Label Phase
Baseline0
Week 22.19
Week 49.29
Week 820.45
Week 1229.09
Week 1844.16
SecondaryDouble Blind Phase: Percentage of Participants With JADAS-27 CRP Minimum Disease Activity at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

Minimum Disease Activity is defined by a JADAS-27 CRP score less than or equal to 3.8 for participants with polyarthritis, and less than or equal to 2 for participants with oligoarthritis. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

Time frame:
Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With JADAS-27 CRP Minimum Disease Activity at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Baseline (Week 18)48.6147.14
Week 2045.8335.71
Week 2447.2234.29
Week 2847.2235.71
Week 3240.2832.86
Week 3644.4430.00
Week 4045.8331.43
Week 4447.2232.86
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.8610 · Difference in percentage: 1.47 · 95% CI -14.96 to 17.90
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.2173 · Difference in percentage: 10.12 · 95% CI -5.96 to 26.20
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.1135 · Difference in percentage: 12.94 · 95% CI -3.08 to 28.96
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.1610 · Difference in percentage: 11.51 · 95% CI -4.58 to 27.60
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.3571 · Difference in percentage: 7.42 · 95% CI -8.37 to 23.21
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0716 · Difference in percentage: 14.44 · 95% CI -1.27 to 30.16
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0746 · Difference in percentage: 14.40 · 95% CI -1.43 to 30.24
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0773 · Difference in percentage: 14.37 · 95% CI -1.57 to 30.30
SecondaryOpen-Label Phase: Percentage of Participants With JADAS-27 CRP Inactive Disease Activity at Week 2, 4, 8, 12 and 18

JADAS-27 inactive disease is defined by a JADAS score less than or equal to 1. JADAS-27 Inactive Disease cutoff values are defined as: 1) Polyarthritis: Inactive Disease: \<=1 and 2) Oligoarthritis (\<4 active joints): Inactive Disease: \<=1. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

Time frame:
Weeks 2, 4, 8, 12 and 18
Reported as:
Number · percentage of participants
Open-Label Phase: Percentage of Participants With JADAS-27 CRP Inactive Disease Activity at Week 2, 4, 8, 12 and 18
percentage of participantsTofacitinib: Open-Label Phase
Week 20
Week 40
Week 82.84
Week 123.64
Week 187.79
SecondaryDouble Blind Phase: Percentage of Participants With JADAS-27 CRP Inactive Disease Activity at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

JADAS-27 inactive disease is defined by a JADAS score less than or equal to 1. JADAS-27 Inactive Disease cutoff values are defined as: 1) Polyarthritis: Inactive Disease: \<=1 and 2) Oligoarthritis (\<4 active joints): Inactive Disease: \<=1. JADAS-27 is a validated composite disease activity measure for JIA. JADAS-27 CRP score was derived from four components; 1) Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]), 2) Parent/legal guardian/subject global assessment of overall well-being (assessed on a VAS of 0 \[very well\] to 10 \[very poor\]), 3) Number of joints with active disease (maximum of 27 and defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness), 4) CRP (measured in milligram per liter \[mg/L\] and value normalized to 0 to 10 scale). The overall JADAS-27 score ranges from 0-57. A higher score indicates more disease activity.

Time frame:
Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With JADAS-27 CRP Inactive Disease Activity at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Baseline (Week 18)6.9410.00
Week 209.722.86
Week 2412.505.71
Week 289.727.14
Week 3211.115.71
Week 3616.677.14
Week 4018.067.14
Week 4418.0610.00
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.5131 · Difference in percentage: -3.06 · 95% CI -12.21 to 6.10
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0876 · Difference in percentage: 6.87 · 95% CI -1.01 to 14.74
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.1561 · Difference in percentage: 6.79 · 95% CI -2.59 to 16.16
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.5795 · Difference in percentage: 2.58 · 95% CI -6.54 to 11.70
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.2435 · Difference in percentage: 5.40 · 95% CI -3.67 to 14.47
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0758 · Difference in percentage: 9.52 · 95% CI -0.99 to 20.04
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0464 · Difference in percentage: 10.91 · 95% CI 0.17 to 21.65
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.1634 · Difference in percentage: 8.06 · 95% CI -3.27 to 19.38
SecondaryDouble Blind Phase: Percentage of Participants With JIA ACR Inactive Disease at Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44

JIA ACR Inactive Disease criteria included: No joints with active arthritis, No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA, No active uveitis (as defined by the Standardized Uveitis Nomenclature (SUN) Working Group), Normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA, Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]) score of 'best possible' (score of "0") on the scale used, morning stiffness of \<=15 minutes.

Time frame:
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With JIA ACR Inactive Disease at Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Baseline (Week 18)9.7227.14
Week 2015.2815.71
Week 2420.8321.43
Week 2819.4418.57
Week 3222.2220.00
Week 3626.3917.14
Week 4026.3914.29
Week 4426.3917.14
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0062 · Difference in percentage: -17.42 · 95% CI -29.88 to -4.96
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.9427 · Difference in percentage: -0.44 · 95% CI -12.34 to 11.47
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.9308 · Difference in percentage: -0.60 · 95% CI -14.03 to 12.84
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.8945 · Difference in percentage: 0.87 · 95% CI -12.03 to 13.78
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.7455 · Difference in percentage: 2.22 · 95% CI -11.20 to 15.64
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.1787 · Difference in percentage: 9.25 · 95% CI -4.23 to 22.72
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.0695 · Difference in percentage: 12.10 · 95% CI -0.97 to 25.17
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.1787 · Difference in percentage: 9.25 · 95% CI -4.23 to 22.72
SecondaryDouble Blind Phase: Percentage of Participants With Presence of JIA ACR Clinical Remission

JIA ACR Clinical Remission Criteria included: Clinical inactive disease for 6 months continuously while on medications for JIA. Clinical Inactive Disease criteria included: No joints with active arthritis, No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to sJIA, No active uveitis (as defined by the SUN Working Group), Normal ESR (within normal limits of the method used where tested) or, if elevated, not attributable to JIA, Physician global assessment of disease activity (assessed on a VAS of 0 \[no activity\] to 10 \[maximum activity\]) score of 'best possible' (score of "0") on the scale used, morning stiffness of less than or equal to (\<=) 15 minutes.

Time frame:
From Week 18 in double blind phase up to Week 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Presence of JIA ACR Clinical Remission
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Double Blind Phase: Percentage of Participants With Presence of JIA ACR Clinical Remission4.174.29
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · Normal approximation to the binomial · p = 0.9719 · Difference in percentage: -0.12 · 95% CI -6.74 to 6.50
SecondaryOpen Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Active Arthritis at Week 2, 4, 8, 12 and 18

Number of joints with active arthritis defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness. The score range of the number of joints is from 0-71.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · joints with active arthritis
Open Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Active Arthritis at Week 2, 4, 8, 12 and 18
joints with active arthritisTofacitinib: Open-Label Phase
Week 2-4.54 ± 5.33
Week 4-7.21 ± 6.36
Week 8-8.62 ± 7.04
Week 12-9.76 ± 6.76
Week 18-10.29 ± 6.79
SecondaryDouble Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Number of Joints With Active Arthritis at Weeks 20, 24, 28, 32, 36, 40 and 44

Number of joints with active arthritis defined as joint with swelling or, in absence of swelling, limited range of motion accompanied by either pain on motion or tenderness. Number of joints ranged from 0 to 71.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Least squares mean · joints with active arthritis
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Number of Joints With Active Arthritis at Weeks 20, 24, 28, 32, 36, 40 and 44
joints with active arthritisTofacitinib: Double Blind PhasePlacebo
Week 200.21 ± 0.481.07 ± 0.49
Week 240.69 ± 0.712.11 ± 0.72
Week 280.46 ± 0.612.13 ± 0.64
Week 320.19 ± 0.481.36 ± 0.51
Week 360.52 ± 0.854.50 ± 0.92
Week 400.91 ± 0.854.48 ± 0.93
Week 440.55 ± 0.742.79 ± 0.77
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.1595 · Ls mean difference: -0.87 · 95% CI -2.08 to 0.35
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.1421 · Ls mean difference: -1.42 · 95% CI -3.32 to 0.48
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0552 · Ls mean difference: -1.66 · 95% CI -3.37 to 0.04
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0822 · Ls mean difference: -1.17 · 95% CI -2.50 to 0.17
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0041 · Ls mean difference: -3.98 · 95% CI -6.53 to -1.43
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0085 · Ls mean difference: -3.57 · 95% CI -6.12 to -1.02
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0384 · Ls mean difference: -2.24 · 95% CI -4.36 to -0.13
SecondaryOpen Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Limited Range of Motion at Weeks 2, 4, 8, 12 and 18

The maximum number of joints with limitation of movement was 67 and these were defined as those in the joint assessment with 'limitation of motion'.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · joints with limited range of motion
Open Label Phase: JIA ACR Core Variable- Change From Baseline in Number of Joints With Limited Range of Motion at Weeks 2, 4, 8, 12 and 18
joints with limited range of motionTofacitinib: Open-Label Phase
Week 2-2.52 ± 4.21
Week 4-3.56 ± 5.68
Week 8-4.53 ± 5.65
Week 12-5.09 ± 5.79
Week 18-5.77 ± 5.82
SecondaryDouble Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Number of Joints With Limited Range of Motion at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44

The maximum number of joints with limitation of movement was 67 and these were defined as those in the joint assessment with 'limitation of motion'.

Time frame:
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Least squares mean · joints with limited range of motion
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Number of Joints With Limited Range of Motion at Double Blind Baseline (Week 18), Week 20, 24, 28, 32, 36, 40 and 44
joints with limited range of motionTofacitinib: Double Blind PhasePlacebo
Week 200.38 ± 0.200.64 ± 0.19
Week 240.50 ± 0.281.19 ± 0.29
Week 280.68 ± 0.351.63 ± 0.37
Week 320.61 ± 0.321.40 ± 0.34
Week 360.47 ± 0.311.48 ± 0.34
Week 400.41 ± 0.341.49 ± 0.39
Week 440.38 ± 0.291.20 ± 0.34
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.2595 · Ls mean difference: -0.26 · 95% CI -0.72 to 0.19
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0674 · Ls mean difference: -0.69 · 95% CI -1.42 to 0.05
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0580 · Ls mean difference: -0.95 · 95% CI -1.93 to 0.03
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0751 · Ls mean difference: -0.79 · 95% CI -1.67 to 0.08
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0251 · Ls mean difference: -1.01 · 95% CI -1.88 to -0.13
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0331 · Ls mean difference: -1.08 · 95% CI -2.07 to -0.09
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0549 · Ls mean difference: -0.82 · 95% CI -1.66 to 0.02
SecondaryOpen Label Phase: JIA ACR Core Variable- Change From Baseline in Physician Global Evaluation of Disease Activity at Week 2, 4, 8, 12 and 18

Physician global evaluation of disease activity was measured on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'No Activity' and '10' as 'Maximum Activity', higher score indicated more disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · score on scale
Open Label Phase: JIA ACR Core Variable- Change From Baseline in Physician Global Evaluation of Disease Activity at Week 2, 4, 8, 12 and 18
score on scaleTofacitinib: Open-Label Phase
Week 2-1.81 ± 1.52
Week 4-2.78 ± 1.84
Week 8-3.51 ± 1.83
Week 12-4.04 ± 1.88
Week 18-4.54 ± 1.92
SecondaryDouble Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at Weeks 20, 24, 28, 32, 36, 40 and 44

Physician global evaluation of disease activity was measured on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'No Activity' and '10' as 'Maximum Activity', higher score indicated more disease activity.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Least squares mean · score on scale
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Physician Global Evaluation of Disease Activity at Weeks 20, 24, 28, 32, 36, 40 and 44
score on scaleTofacitinib: Double Blind PhasePlacebo
Week 200.28 ± 0.200.82 ± 0.20
Week 240.24 ± 0.241.08 ± 0.24
Week 280.12 ± 0.210.92 ± 0.92
Week 32-0.03 ± 0.200.86 ± 0.22
Week 360.14 ± 0.281.56 ± 0.32
Week 400.02 ± 0.281.64 ± 0.32
Week 44-0.16 ± 0.291.42 ± 0.34
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0353 · Ls mean difference: -0.54 · 95% CI -1.04 to -0.04
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0094 · Ls mean difference: -0.84 · 95% CI -1.47 to -0.21
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0065 · Ls mean difference: -0.80 · 95% CI -1.36 to -0.23
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0018 · Ls mean difference: -0.89 · 95% CI -1.43 to -0.34
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0010 · Ls mean difference: -1.42 · 95% CI -2.24 to -0.61
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0002 · Ls mean difference: -1.61 · 95% CI -2.42 to -0.81
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0007 · Ls mean difference: -1.58 · 95% CI -2.44 to -0.71
SecondaryOpen Label Phase: JIA ACR Core Variable- Change From Baseline in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Weeks 2, 4, 8, 12 and 18

The parent/or legal guardian/participant rated the overall well-being on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'Very Well' and '10' as 'Very Poorly', higher scores=more disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · score on scale
Open Label Phase: JIA ACR Core Variable- Change From Baseline in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Weeks 2, 4, 8, 12 and 18
score on scaleTofacitinib: Open-Label Phase
Week 2-0.94 ± 1.95
Week 4-1.47 ± 1.92
Week 8-1.90 ± 2.20
Week 12-2.30 ± 2.15
Week 18-2.68 ± 2.33
SecondaryDouble Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Weeks 20, 24, 28, 32, 36, 40 and 44

The parent/or legal guardian/participant rated the overall well-being on a 21-numbered circle VAS ranges from 0 to 10 (in 0.5 increments), with '0' as 'Very Well' and '10' as 'Very Poorly', higher scores=more disease activity.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Least squares mean · score on scale
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Parent/Legal Guardian/Participant Global Evaluation of Overall Well-Being at Weeks 20, 24, 28, 32, 36, 40 and 44
score on scaleTofacitinib: Double Blind PhasePlacebo
Week 20-0.04 ± 0.180.38 ± 0.18
Week 24-0.03 ± 0.220.91 ± 0.22
Week 28-0.11 ± 0.240.72 ± 0.26
Week 32-0.15 ± 0.240.82 ± 0.26
Week 36-0.22 ± 0.210.31 ± 0.24
Week 40-0.24 ± 0.240.39 ± 0.27
Week 44-0.49 ± 0.220.24 ± 0.24
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0398 · Ls mean difference: -0.42 · 95% CI -0.83 to -0.02
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0011 · Ls mean difference: -0.94 · 95% CI -1.49 to -0.39
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0131 · Ls mean difference: -0.82 · 95% CI -1.47 to -0.18
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0039 · Ls mean difference: -0.97 · 95% CI -1.62 to -0.33
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0711 · Ls mean difference: -0.53 · 95% CI -1.10 to 0.05
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0658 · Ls mean difference: -0.63 · 95% CI -1.30 to 0.04
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0154 · Ls mean difference: -0.73 · 95% CI -1.31 to -0.15
SecondaryOpen Label Phase: JIA ACR Core Variable- Change From Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Scores at Weeks 2, 4, 8, 12 and 18

CHAQ is a valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate the overall score, the participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from baseline at Weeks 2, 4, 8, 12 and 18 in DI total score is reported.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · score on scale
Open Label Phase: JIA ACR Core Variable- Change From Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Scores at Weeks 2, 4, 8, 12 and 18
score on scaleTofacitinib: Open-Label Phase
Week 2-0.15 ± 0.41
Week 4-0.23 ± 0.42
Week 8-0.36 ± 0.46
Week 12-0.41 ± 0.53
Week 18-0.49 ± 0.57
SecondaryDouble Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Scores at Weeks 20, 24, 28, 32, 36, and 40

CHAQ: valid assessment of functional disability, discomfort in participants with rheumatic diseases. It comprises of three indices: Disability and Discomfort, and global assessment of arthritis (overall well-being). CHAQ-DI: as a measure of functional ability, consists of 30 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities-distributed, among a total of 30 items. Each question was rated on a 4-point scale of difficulty in performance ranges from 0 (no difficulty) to 3 (unable to do). To calculate overall score, participant must have a domain score in at least 6 of the 8 domains. Scores of 8 domains were averaged to calculate the CHAQ-DI total score which ranges from 0 (no or minimal physical dysfunction) to 3 (very severe physical dysfunction), higher score indicates more disability. Change from double-blind baseline at Weeks 20, 24, 28, 32, 36, and 40 in DI total score is reported.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, and 40
Reported as:
Least squares mean · score on scale
Double Blind Phase: JIA ACR Core Variable- Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire- Disability Index (CHAQ-DI) Total Scores at Weeks 20, 24, 28, 32, 36, and 40
score on scaleTofacitinib: Double Blind PhasePlacebo
Week 200.05 ± 0.040.08 ± 0.04
Week 240.01 ± 0.030.08 ± 0.04
Week 28-0.01 ± 0.040.09 ± 0.04
Week 320.01 ± 0.040.10 ± 0.05
Week 36-0.04 ± 0.040.08 ± 0.05
Week 40-0.05 ± 0.040.06 ± 0.05
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.4777 · Ls mean difference: -0.03 · 95% CI -0.12 to 0.06
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0779 · Ls mean difference: -0.07 · 95% CI -0.16 to 0.01
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0324 · Ls mean difference: -0.10 · 95% CI -0.19 to -0.01
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.1061 · Ls mean difference: -0.09 · 95% CI -0.20 to 0.02
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0572 · Ls mean difference: -0.12 · 95% CI -0.24 to 0.00
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0689 · Ls mean difference: -0.11 · 95% CI -0.24 to 0.01
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0292 · Ls mean difference: -0.12 · 95% CI -0.22 to -0.01
SecondaryOpen-Label Phase: Change From Baseline in Child Health Questionnaire (CHQ) Responses at Week 4 and Week 18

CHQ: 50-item, 14 subscale (Global health, physical functioning, social limitations: emotional, social limitations: physical, bodily pain, behavior, global behavior, mental health, self-esteem, general health, Change in health, emotional impact on parent, time impact on parent, family activities, family cohesion) parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents. Each subscale rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Two summary scores: Physical Health and Psychosocial Health were weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.

Time frame:
Baseline, Week 4 and Week 18
Reported as:
Mean · score on scale
Open-Label Phase: Change From Baseline in Child Health Questionnaire (CHQ) Responses at Week 4 and Week 18
score on scaleTofacitinib: Open-Label Phase
Week 4: Global health13.86 ± 22.40
Week 18: Global health21.28 ± 22.79
Week 4: Physical functioning11.83 ± 24.47
Week 18: Physical functioning21.44 ± 26.78
Week 4: Social limitations: emotional8.12 ± 29.29
Week 18: Social limitations: emotional14.62 ± 30.18
Week 4: Social limitations: physical13.45 ± 31.12
Week 18: Social limitations: physical20.81 ± 32.53
Week 4: Bodily pain19.42 ± 21.14
Week 18: Bodily pain30.60 ± 22.79
Week 4: Behavior3.06 ± 12.86
Week 18: Behavior5.70 ± 12.91
Week 4: Global behavior7.40 ± 23.27
Week 18: Global behavior9.30 ± 24.97
Week 4: Mental health6.43 ± 15.68
Week 18: Mental health6.74 ± 16.06
Week 4: Self esteem2.42 ± 19.47
Week 18: Self esteem8.45 ± 17.35
Week 4: General health4.20 ± 13.50
Week 18: General health7.02 ± 14.31
Week 4: Change in Health0.86 ± 1.20
Week 18: Change in Health1.70 ± 1.32
Week 4: Emotional impact on parent9.02 ± 26.30
Week 18: Emotional impact on parent15.38 ± 29.35
Week 4: Time impact on parent6.17 ± 24.64
Week 18: Time impact on parent9.99 ± 23.38
Week 4: Family activities5.19 ± 15.15
Week 18: Family activities9.59 ± 19.63
Week 4: Family cohesion2.78 ± 21.80
Week 18: Family cohesion3.62 ± 18.81
Week 4: Physical Health Summary8.12 ± 11.18
Week 18: Physical Health Summary13.36 ± 12.57
Week 4: Psychosocial Health Summary2.46 ± 8.13
Week 18: Psychosocial Health Summary4.20 ± 8.41
SecondaryDouble Blind Phase: Change From Double-Blind Baseline in Child Health Questionnaire (CHQ) Responses at Week 44

CHQ: 50-item, 14 subscale (Global health, physical functioning, social limitations: emotional, social limitations: physical, bodily pain, behavior, global behavior, mental health, self-esteem, general health, Change in health, emotional impact on parent, time impact on parent, family activities, family cohesion) parent or legal guardian assessed instrument of child's physical, emotional, social well-being, and relative burden of disease on the parents. Each subscale rated on Likert-type scale: range 0 to 100; higher scores indicate a more positive health status. Two summary scores: Physical Health and Psychosocial Health were weighted composites derived from subscale items using scoring algorithms (transformed scores); range 0 to 100: higher scores indicate more positive health status.

Time frame:
Double-Blind Baseline (Week 18), Week 44
Reported as:
Least squares mean · score on a scale
Double Blind Phase: Change From Double-Blind Baseline in Child Health Questionnaire (CHQ) Responses at Week 44
score on a scaleTofacitinib: Double Blind PhasePlacebo
Global health5.46 ± 2.831.66 ± 3.72
Physical functioning1.45 ± 3.16-1.82 ± 3.92
Social Limitations: Emotional1.78 ± 3.53-3.69 ± 4.36
Social Limitations: Physical-3.08 ± 4.03-10.29 ± 5.04
Bodily Pain6.34 ± 3.13-1.91 ± 3.91
Behavior0.78 ± 2.094.20 ± 2.57
Global Behavior-2.61 ± 2.891.04 ± 3.54
Mental Health0.41 ± 2.533.88 ± 3.12
Self Esteem1.48 ± 3.290.76 ± 4.07
General Health7.91 ± 1.846.14 ± 2.26
Change in Health0.07 ± 0.100.09 ± 0.12
Emotional Impact on Parent9.55 ± 4.320.58 ± 5.35
Time Impact on Parent-3.83 ± 2.922.89 ± 3.62
Family Activities0.01 ± 2.398.61 ± 2.95
Family Cohesion6.04 ± 3.183.45 ± 3.92
Physical Health Summary1.67 ± 1.48-1.81 ± 1.85
Psychosocial Health Summary0.64 ± 1.221.39 ± 1.52
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.3179 · Ls mean difference: 3.79 · 95% CI -3.72 to 11.31
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.4452 · Ls mean difference: 3.28 · 95% CI -5.23 to 11.78
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.2539 · Ls mean difference: 5.47 · 95% CI -4.01 to 14.95
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.1981 · Ls mean difference: 7.22 · 95% CI -3.86 to 18.30
  • Tofacitinib: Double Blind Phase · MMRM · p = 0.0620 · Ls mean difference: 8.26 · 95% CI -0.43 to 16.94
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.2291 · Ls mean difference: -3.43 · 95% CI -9.06 to 2.20
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.3530 · Ls mean difference: -3.65 · 95% CI -11.43 to 4.13
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.3114 · Ls mean difference: -3.47 · 95% CI -10.26 to 3.32
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.8736 · Ls mean difference: 0.71 · 95% CI -8.18 to 9.61
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.4778 · Ls mean difference: 1.77 · 95% CI -3.18 to 6.72
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.8909 · Ls mean difference: -0.02 · 95% CI -0.28 to 0.25
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.1270 · Ls mean difference: 8.97 · 95% CI -2.61 to 20.55
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0944 · Ls mean difference: -6.72 · 95% CI -14.62 to 1.18
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0095 · Ls mean difference: -8.60 · 95% CI -15.03 to -2.17
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.5474 · Ls mean difference: 2.59 · 95% CI -5.96 to 11.14
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0902 · Ls mean difference: 3.48 · 95% CI -0.56 to 7.52
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.6539 · Ls mean difference: -0.75 · 95% CI -4.07 to 2.57
SecondaryOpen Label Phase: Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Weeks 2, 4, 8, 12 and 18

CHAQ is a validated instrument and comprises of two indices, Disability and Discomfort, and global assessment of arthritis (overall well-being). Discomfort Index included: assessment of discomfort, the parent/legal guardian/participant were asked to provide a response to the question: How much pain do you think your child had because of his or her illness in the past week?, The parent/legal guardian/ participant rated the overall pain on a 0 to 10 VAS, where '0' indicates 'No Pain' and '10' indicates 'Very Severe Pain', higher scores indicates more severity.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · score on scale
Open Label Phase: Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Weeks 2, 4, 8, 12 and 18
score on scaleTofacitinib: Open-Label Phase
Week 2-1.32 ± 2.10
Week 4-2.06 ± 2.16
Week 8-2.38 ± 2.40
Week 12-2.72 ± 2.28
Week 18-3.04 ± 2.57
SecondaryDouble Blind Phase:Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Weeks 20, 24, 28, 32, 36, 40 and 44

CHAQ is a validated instrument and comprises of two indices, Disability and Discomfort, and global assessment of arthritis (overall well-being). Discomfort Index included: assessment of discomfort, the parent/legal guardian/participant were asked to provide a response to the question: How much pain do you think your child had because of his or her illness in the past week?, The parent/legal guardian/ participant rated the overall pain on a 0 to 10 VAS, where '0' indicates 'No Pain' and '10' indicates 'Very Severe Pain', higher scores indicates more severity.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36,40 and 44
Reported as:
Mean · score on scale
Double Blind Phase:Change From Double-Blind Baseline in Childhood Health Assessment Questionnaire (CHAQ)- Discomfort Index at Weeks 20, 24, 28, 32, 36, 40 and 44
score on scaleTofacitinib: Double Blind PhasePlacebo
Week 200.08 ± 0.200.40 ± 0.20
Week 24-0.01 ± 0.240.94 ± 0.24
Week 28-0.23 ± 0.240.64 ± 0.25
Week 320.07 ± 0.271.06 ± 0.29
Week 36-0.21 ± 0.210.32 ± 0.24
Week 40-0.22 ± 0.240.49 ± 0.26
Week 44-0.36 ± 0.230.44 ± 0.25
Statistical analysis
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.1894 · Ls mean difference: -0.32 · 95% CI -0.80 to 0.16
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0026 · Ls mean difference: -0.95 · 95% CI -1.56 to -0.34
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0067 · Ls mean difference: -0.87 · 95% CI -1.50 to -0.25
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0091 · Ls mean difference: -0.99 · 95% CI -1.73 to -0.25
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0632 · Ls mean difference: -0.53 · 95% CI -1.09 to 0.03
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0306 · Ls mean difference: -0.71 · 95% CI -1.35 to -0.07
  • Tofacitinib: Double Blind Phase vs Placebo · MMRM · p = 0.0118 · Ls mean difference: -0.80 · 95% CI -1.41 to -0.18
SecondaryOpen-Label Phase: Percentage of Participants With Active Uveitis at Baseline

Uveitis is the inflammation of the uvea. Participants were assessed for presence of uveitis (according to Standard Uveitis Nomenclature \[SUN\]). If Uveitis was present in participant at Baseline, it was considered as "active uveitis"; If Uveitis was not present in participant at Baseline, it was considered as "Inactive uveitis". As per SUN, Uveitis is defined as: anterior (in which anterior chamber is primary site of inflammation); intermediate (primary site of inflammation: vitreous); posterior (primary site of inflammation: retina or choroid). Percentage of participants with active uveitis (of any type) are reported.

Time frame:
Baseline
Reported as:
Number · percentage of participants
Open-Label Phase: Percentage of Participants With Active Uveitis at Baseline
percentage of participantsTofacitinib: Open-Label Phase
Open-Label Phase: Percentage of Participants With Active Uveitis at Baseline0.0
SecondaryDouble Blind Phase: Percentage of Participants With Active Uveitis at Week 24 and Week 44

Uveitis is the inflammation of the uvea. Participants were assessed for presence of uveitis (according to Standard Uveitis Nomenclature \[SUN\]). If Uveitis was present in participant at Baseline, it was considered as "active uveitis"; If Uveitis was not present in participant at Baseline, it was considered as "Inactive uveitis". As per SUN, Uveitis is defined as: anterior (in which anterior chamber is primary site of inflammation); intermediate (primary site of inflammation: vitreous); posterior (primary site of inflammation: retina or choroid). Percentage of participants with active uveitis (of any type) are reported.

Time frame:
Week 24 and Week 44
Reported as:
Number · percentage of participants
Double Blind Phase: Percentage of Participants With Active Uveitis at Week 24 and Week 44
percentage of participantsTofacitinib: Double Blind PhasePlacebo
Week 24: Present0.01.2
Week 44: Present0.00.0
SecondaryOpen-Label Phase: Change From Baseline in the Tender Entheseal Assessment at Weeks 2, 4, 8, 12 and 18

Participants with enthesitis-related arthritis (ERA) undergo Tender entheseal assessment. Tender entheseal assessment: Entheses were assessed and coded as: 1= any tenderness, 0= no tenderness, NE= not evaluable. Total number of tender entheses: 66\*(total number of tender entheses with counts \> 0)/number of non-missing tender entheses. If \> 33 tender entheseal counts were missing, total number of tender entheses was defined as missing.

Time frame:
Baseline, weeks 2, 4, 8, 12 and 18
Reported as:
Mean · tender entheses score
Open-Label Phase: Change From Baseline in the Tender Entheseal Assessment at Weeks 2, 4, 8, 12 and 18
tender entheses scoreTofacitinib: Open-Label Phase
Week 2-1.57 ± 3.61
Week 4-2.52 ± 3.92
Week 8-3.05 ± 4.45
Week 12-3.15 ± 4.93
Week 18-3.50 ± 4.70
SecondaryDouble Blind Phase: Change From Double-Blind Baseline in the Tender Entheseal Assessment at Weeks 20, 24, 28, 32, 36, 40 and 44

Participants with ERA undergo Tender entheseal assessment. Tender entheseal assessment: Entheses were assessed and coded as: 1= any tenderness, 0= no tenderness, NE= not evaluable. Total number of tender entheses: 66\*(total number of tender entheses with counts \> 0)/number of non-missing tender entheses. If \> 33 tender entheseal counts were missing, total number of tender entheses was defined as missing.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Mean · tender entheses score
Double Blind Phase: Change From Double-Blind Baseline in the Tender Entheseal Assessment at Weeks 20, 24, 28, 32, 36, 40 and 44
tender entheses scoreTofacitinib: Double Blind PhasePlacebo
Week 200.00 ± 0.870.86 ± 2.61
Week 24-1.00 ± 3.460.40 ± 2.19
Week 28-0.43 ± 2.57-0.75 ± 0.96
Week 320.33 ± 1.970.00 ± 0.82
Week 36-0.83 ± 2.040.33 ± 0.58
Week 40-2.00 ± 4.470.33 ± 0.58
Week 44-2.00 ± 5.66-0.33 ± 0.58
SecondaryOpen-Label Phase: Change From Baseline in the Modified Schober's Test at Week 2, 4, 8, 12 and 18

Participants with ERA undergo Modified Schober's Test. In the Modified Schober's Test, a mark was placed 5 cm below the midpoint of a line that joined the posterior superior iliac spines. Another mark was placed 10 cm above the first. The participant then bent maximally forward with the knees fully extended. The distance between the two marks was then re-measured. The full measurement between the two lines was recorded to the nearest tenth of a centimeter and is reported.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · centimeter (cm)
Open-Label Phase: Change From Baseline in the Modified Schober's Test at Week 2, 4, 8, 12 and 18
centimeter (cm)Tofacitinib: Open-Label Phase
Week 2-0.35 ± 1.02
Week 4-0.20 ± 1.03
Week 8-0.12 ± 1.15
Week 120.02 ± 1.05
Week 180.29 ± 1.08
SecondaryDouble Blind Phase: Change From Double Blind Baseline in the Modified Schober's Test at Week 20, 24, 28, 32, 36, 40 and 44

Participants with ERA undergo Modified Schober's Test. In the Modified Schober's Test, a mark was placed 5 cm below the midpoint of a line that joined the posterior superior iliac spines. Another mark was placed 10 cm above the first. The participant then bent maximally forward with the knees fully extended. The distance between the two marks was then re-measured. The full measurement between the two lines was recorded to the nearest tenth of a centimeter and is reported.

Time frame:
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Mean · cm
Double Blind Phase: Change From Double Blind Baseline in the Modified Schober's Test at Week 20, 24, 28, 32, 36, 40 and 44
cmTofacitinib: Double Blind PhasePlacebo
Week 20-0.46 ± 1.61-0.28 ± 0.47
Week 24-0.44 ± 1.27-0.35 ± 0.54
Week 280.32 ± 1.38-0.17 ± 0.57
Week 320.42 ± 1.840.63 ± 1.26
Week 36-0.53 ± 0.840.05 ± 0.21
Week 400.57 ± 1.620.85 ± 0.64
Week 440.50 ± 0.871.05 ± 2.47
SecondaryOpen-Label Phase: Change From Baseline in the Overall Back Pain and Nocturnal Back Pain Responses at Week 2, 4, 8, 12 and 18

Participants with ERA undergo Overall Back Pain and Nocturnal Back Pain assessment. For Overall Back Pain, parent/legal guardian/participant were asked to provide a response to the question: What is the amount of back pain at any time that your child experienced in the past week? And For Nocturnal Back Pain: What is the amount of back pain at night that your child experienced in the past week?. Response to these questions was provided by parent/legal guardian/participant using a VAS of 0-10, where 0= No Pain and 10= Most Severe Pain, higher score indicated more severe pain.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · score on scale
Open-Label Phase: Change From Baseline in the Overall Back Pain and Nocturnal Back Pain Responses at Week 2, 4, 8, 12 and 18
score on scaleTofacitinib: Open-Label Phase
Week 2: Nocturnal Back Pain-1.21 ± 3.10
Week 4: Nocturnal Back Pain-1.33 ± 3.44
Week 8: Nocturnal Back Pain-1.80 ± 3.18
Week 12: Nocturnal Back Pain-2.30 ± 2.63
Week 18: Nocturnal Back Pain-1.98 ± 2.94
Week 2: Overall back pain-1.81 ± 2.89
Week 4: Overall back pain-1.86 ± 3.29
Week 8:Overall back pain-2.65 ± 2.72
Week 12:Overall back pain-3.20 ± 2.54
Week 18: Overall back pain-3.30 ± 2.45
SecondaryDouble Blind Phase: Change From Double-Blind Baseline in the Overall Back Pain and Nocturnal Back Pain Responses at Week 20, 24, 28, 32, 36, 40 and 44

Participants with ERA undergo Overall Back Pain and Nocturnal Back Pain assessment. For Overall Back Pain, parent/legal guardian/participant were asked to provide a response to the question: What is the amount of back pain at any time that your child experienced in the past week? And For Nocturnal Back Pain: What is the amount of back pain at night that your child experienced in the past week?. Response to these questions was provided by parent/legal guardian/participant using a VAS of 0-10, where 0= No Pain and 10= Most Severe Pain, higher score indicated more severe pain.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Mean · score on scale
Double Blind Phase: Change From Double-Blind Baseline in the Overall Back Pain and Nocturnal Back Pain Responses at Week 20, 24, 28, 32, 36, 40 and 44
score on scaleTofacitinib: Double Blind PhasePlacebo
Week 20: Nocturnal Back Pain-0.17 ± 0.870.57 ± 0.93
Week 24: Nocturnal Back Pain-1.06 ± 1.960.10 ± 0.42
Week 28: Nocturnal Back Pain-0.79 ± 2.000.00 ± 0.41
Week 32: Nocturnal Back Pain-1.58 ± 1.630.38 ± 0.63
Week 36: Nocturnal Back Pain-0.75 ± 2.270.17 ± 0.29
Week 40: Nocturnal Back Pain-2.00 ± 2.260.17 ± 0.29
Week 44: Nocturnal Back Pain-0.80 ± 2.200.17 ± 0.29
Week 20: Overall back pain0.28 ± 1.890.57 ± 1.40
Week 24: Overall back pain0.39 ± 2.100.00 ± 0.79
Week 28: Overall back pain0.00 ± 2.60-0.25 ± 0.29
Week 32:Overall back pain-1.75 ± 2.25-0.13 ± 0.48
Week 36: Overall back pain0.17 ± 1.29-0.50 ± 0.87
Week 40: Overall back pain0.30 ± 1.79-0.50 ± 0.87
Week 44: Overall back pain-0.10 ± 3.45-0.50 ± 0.87
SecondaryOpen-Label Phase: Changes From Baseline in Percentage of Body Surface Area (BSA) Affected With Psoriasis at Weeks 2, 4, 8, 12 and 18

Percentage of body surface area affected by psoriasis was estimated using the palm method. One of the participant's palm to proximal interphalangeal (PIP) and thumb =\\together represented 1% of total BSA. Regions of the body were assigned specific number of palms with percentage (Head and Neck = 10% \[10 palms\], Upper extremities = 20% \[20 palms\], Trunk \[axillae and groin\] = 30% \[30 palms\], Lower extremities \[buttocks\] = 40% \[40 palms\]). The number of palms of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · percentage of BSA
Open-Label Phase: Changes From Baseline in Percentage of Body Surface Area (BSA) Affected With Psoriasis at Weeks 2, 4, 8, 12 and 18
percentage of BSATofacitinib: Open-Label Phase
Week 20.55 ± 4.70
Week 4-1.03 ± 2.49
Week 8-0.29 ± 6.11
Week 12-0.36 ± 5.93
Week 18-0.46 ± 6.48
SecondaryDouble Blind Phase: Changes From Double Blind Baseline in Body Surface Area (BSA) Affected With Psoriasis at Week 20, 24, 28, 32, 36, 40 and 44

Percentage of body surface area affected by psoriasis was estimated using the palm method. One of the participant's palm to PIP and thumb together represented 1% of total BSA. Regions of the body were assigned specific number of palms with percentage (Head and Neck = 10% \[10 palms\], Upper extremities = 20% \[20 palms\], Trunk \[axillae and groin\] = 30% \[30 palms\], Lower extremities \[buttocks\] = 40% \[40 palms\]). The number of palms of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.

Time frame:
Double Blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Mean · percentage of BSA
Double Blind Phase: Changes From Double Blind Baseline in Body Surface Area (BSA) Affected With Psoriasis at Week 20, 24, 28, 32, 36, 40 and 44
percentage of BSATofacitinib: Double Blind PhasePlacebo
Week 20-0.50 ± 1.220.28 ± 0.70
Week 24-0.14 ± 0.380.85 ± 1.71
Week 28-4.20 ± 8.840.33 ± 0.58
Week 32-0.60 ± 1.341.67 ± 2.89
Week 36-4.20 ± 8.901.33 ± 2.31
Week 40-4.60 ± 8.710.67 ± 1.15
Week 44-4.60 ± 8.71-0.05 ± 0.07
SecondaryOpen-Label Phase: Changes From Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Weeks 2, 4, 8, 12 and 18

The PGA of psoriasis was scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 5 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and ranged as 0= no symptom to 5=severe, higher score indicates more severity.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Mean · score on scale
Open-Label Phase: Changes From Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Weeks 2, 4, 8, 12 and 18
score on scaleTofacitinib: Open-Label Phase
Week 2-0.05 ± 0.39
Week 4-0.42 ± 0.84
Week 8-0.29 ± 0.92
Week 12-0.56 ± 0.86
Week 18-0.56 ± 1.03
SecondaryDouble Blind Phase:Change From Double-Blind Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Weeks 20, 24, 28, 32, 36, 40 and 44

The PGA of psoriasis was scored on a 6-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 5 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and ranged as 0= no symptom to 5=severe, higher score indicates more severity.

Time frame:
Double blind Baseline (Week 18), Weeks 20, 24, 28, 32, 36, 40 and 44
Reported as:
Mean · score on scale
Double Blind Phase:Change From Double-Blind Baseline in Physician's Global Assessment (PGA) of Psoriasis Assessments at Weeks 20, 24, 28, 32, 36, 40 and 44
score on scaleTofacitinib: Double Blind PhasePlacebo
Week 200.14 ± 0.380.00 ± 0.00
Week 240.14 ± 0.380.38 ± 0.52
Week 280.20 ± 0.450.33 ± 0.58
Week 320.00 ± 0.000.33 ± 0.58
Week 360.00 ± 0.000.33 ± 0.58
Week 400.00 ± 0.000.00 ± 0.00
Week 440.00 ± 0.00-0.50 ± 0.71
SecondaryOpen-Label Phase: Taste Assessment of Tofacitinib Oral Solution on Day 14

Oral solution was given only to participants weighing \<40 kg and to the participants who were unable to swallow tablets. Taste assessment was evaluated using a 5 categories questionnaire. Participants were asked to answer in one of the following categories to describe the taste of oral solution of tofacitinib: dislike very much, dislike a little, not sure, like a little and like very much. Number of participants within each category are reported.

Time frame:
Day 14
Reported as:
Count of participants · Participants
Open-Label Phase: Taste Assessment of Tofacitinib Oral Solution on Day 14
ParticipantsTofacitinib: Open-Label Phase
Dislike Very Much4
Dislike a Little8
Not Sure6
Like a Little32
Like Very Much34
SecondaryOpen-Label Phase: Number of Participants With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases

Serious infection defined as any infection that requires hospitalization for treatment or requires parenteral antimicrobial therapy or meets other criteria that require it to be classified as a serious adverse event. Cytopenia was categorized as: lymphocyte counts: \<500 lymphocytes/ millimeter\^3 (mm), neutrophil counts \<1000 neutrophils/mm\^3, platelet counts \<100,000 platelets/mm\^3, any single hemoglobin value \<8 grams/decilitre (g/dL) and any single hemoglobin value drops \>=2 g/dL below baseline. Number of Participants With serious infections, cytopenia, malignancies and Cardiovascular Diseases are reported.

Time frame:
From the first dose of study drug up to Week 18
Reported as:
Count of participants · Participants
Open-Label Phase: Number of Participants With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases
ParticipantsTofacitinib: Open-Label Phase
Serious Infections3
Cytopenia: Lymphocyte counts <500 lymphocytes/mm^31
Cytopenia:Neutrophil counts <1000 neutrophils/mm^34
Cytopenia: Platelet counts <100,000 platelets/mm^31
Cytopenia: Any single hg value <8 g/dL1
Cytopenia:Any hg value drops>=2g/dL below baseline17
Malignancies0
Cardiovascular Diseases0
SecondaryDouble Blind Phase: Number of Participants With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases

Serious infection defined as any infection that requires hospitalization for treatment or requires parenteral antimicrobial therapy or meets other criteria that require it to be classified as a serious adverse event. Cytopenia was categorized as: lymphocyte counts \<500 lymphocytes/mm\^3, neutrophil counts \<1000 neutrophils/mm\^3, platelet counts \<100000 platelets/mm\^3, any single hemoglobin (hg) value \<8 g/dL and any single hemoglobin value drops \>=2 g/dL below baseline. Number of Participants With serious infections, cytopenia, malignancies and Cardiovascular Diseases are reported.

Time frame:
From the first dose of study drug in double blind up to week 44
Reported as:
Count of participants · Participants
Double Blind Phase: Number of Participants With Serious Infections, Cytopenia, Malignancies and Cardiovascular Diseases
ParticipantsTofacitinib: Double Blind PhasePlacebo
Serious Infections01
Cytopenia: Lymphocyte counts <500 lymphocytes/mm^300
Cytopenia:Neutrophil counts <1000 neutrophils/mm^302
Cytopenia: Platelet counts <100,000 platelets/mm^310
Cytopenia: Any single hemoglobin value <8 g/dL00
Cytopenia: hg value drops >=2 g/dL below baseline37
Malignancies00
Cardiovascular Diseases00
SecondaryOpen-Label Phase: Number of Participants With Tanner Staging Evaluation (Pubic Hair)

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: no hair, Stage 2: downy hair, Stage 3: Scant terminal hair, Stage 4: Terminal hair that fills the entire triangle overlying the pubic region and Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh. Tanner Stage for pubic hair at Day 1 was summarized and reported using number of participants in each stage.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Open-Label Phase: Number of Participants With Tanner Staging Evaluation (Pubic Hair)
ParticipantsTofacitinib: Open-Label Phase
Stage 173
Stage 221
Stage 325
Stage 447
Stage 552
SecondaryDouble Blind Phase: Number of Participants With Tanner Staging Evaluation (Pubic Hair)

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males) were assessed in this study and with values in the scale ranging from: Stage 1: no hair, Stage 2: downy hair, Stage 3: Scant terminal hair, Stage 4: Terminal hair that fills the entire triangle overlying the pubic region and Stage 5: Terminal hair that extends beyond the inguinal crease onto the thigh. Tanner Stage for pubic hair at Week 44 was summarized and reported using number of participants in each stage.

Time frame:
Week 44
Reported as:
Count of participants · Participants
Double Blind Phase: Number of Participants With Tanner Staging Evaluation (Pubic Hair)
ParticipantsTofacitinib: Double Blind PhasePlacebo
Stage 1137
Stage 287
Stage 383
Stage 4144
Stage 51317
SecondaryOpen-Label Phase: Number of Participants With Tanner Staging Evaluation (Breast Exam)

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: No glandular breast tissue palpable, Stage 2: Breast bud palpable under areola (1st pubertal sign in females), Stage 3: Breast tissue palpable outside areola; no areolar development, Stage 4: Areola elevated above contour of the breast, forming "double scoop" appearance, Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion. Tanner Stage for Breast at Day 1 was summarized and reported using number of participants in each stage.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Open-Label Phase: Number of Participants With Tanner Staging Evaluation (Breast Exam)
ParticipantsTofacitinib: Open-Label Phase
Stage 142
Stage 219
Stage 328
Stage 434
Stage 540
SecondaryDouble Blind Phase: Number of Participants With Tanner Staging Evaluation (Breast Exam)

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: No glandular breast tissue palpable, Stage 2: Breast bud palpable under areola (1st pubertal sign in females), Stage 3: Breast tissue palpable outside areola; no areolar development, Stage 4: Areola elevated above contour of the breast, forming "double scoop" appearance, Stage 5: Areolar mound recedes back into single breast contour with areolar hyperpigmentation, papillae development and nipple protrusion. Tanner Stage for Breast at Week 44 was summarized and reported using number of participants in each stage.

Time frame:
Week 44
Reported as:
Count of participants · Participants
Double Blind Phase: Number of Participants With Tanner Staging Evaluation (Breast Exam)
ParticipantsTofacitinib: Double Blind PhasePlacebo
Stage 168
Stage 282
Stage 372
Stage 4133
Stage 5913
SecondaryOpen-Label Phase: Number of Participants With Tanner Staging Evaluation (Genitalia)

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: Testicular volume \< 4 ml or long axis \< 2.5 cm, Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males, Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long), Stage 4: 15-20 ml (or 4.1-4.5 cm long), Stage 5: \> 20 ml (or \> 4.5 cm long). Tanner Stage for genitalia at Day 1 was summarized and reported using number of participants in each stage.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Open-Label Phase: Number of Participants With Tanner Staging Evaluation (Genitalia)
ParticipantsTofacitinib: Open-Label Phase
Stage 124
Stage 26
Stage 38
Stage 411
Stage 56
SecondaryDouble Blind Phase: Number of Participants With Tanner Staging Evaluation (Genitalia)

Tanner stage is a scale used to document the stage of development of puberty by assessing the secondary sexual characteristics: Pubic hair (both male and female), breast size (for females); and size of the genitalia (for males).were assessed in this study and with values in the scale ranging from: Stage 1: Testicular volume \< 4 ml or long axis \< 2.5 cm, Stage 2: 4 ml-8 ml (or 2.5-3.3 cm long), 1st pubertal sign in males, Stage 3: 9 ml-12 ml (or 3.4-4.0 cm long), Stage 4: 15-20 ml (or 4.1-4.5 cm long), Stage 5: \> 20 ml (or \> 4.5 cm long). Tanner Stage for genitalia at Week 44 was summarized and reported using number of participants in each stage.

Time frame:
Week 44
Reported as:
Count of participants · Participants
Double Blind Phase: Number of Participants With Tanner Staging Evaluation (Genitalia)
ParticipantsTofacitinib: Double Blind PhasePlacebo
Stage 150
Stage 205
Stage 320
Stage 451
Stage 514
SecondaryOpen-Label Phase: Number of Participants With Laboratory Abnormalities

Criteria: Hemoglobin(Hg),hematocrit erythrocytes(Ery); \<0.8\*lower limit of normal (LLN), Ery. Mean Corpuscular Volume; \<0.9\*LLN, \>1.1\*upper limit of normal (ULN), Platelets; \<0.5\*LLN, \>1.75\*ULN, Leukocytes (leu); \<0.6\*LLN, \>1.5\*ULN, Lymphocytes (Ly), Ly/leu, Neutrophils, Neutrophils/leu \<0.8\*LLN, Basophils/leu, Eosinophils, Eosinophils/leu, Monocytes, Monocytes/leu \>1.2\*ULN, Ery Sedimentation Rate \>1.5\*ULN. Bilirubin, Indirect Bilirubin \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase, Alkaline Phosphatase \>3.0\*ULN, Albumin \>1.2\*ULN, Creatinine \>1.3\*ULN, HDL Cholesterol (Chol)\<0.8\*LLN, LDL Chol, LDL Chol Friedewald Est PEG \>1.2\*ULN, Triglycerides \>1.3\*ULN, Calcium \<0.9\*LLN, Bicarbonate \<0.9\*LLN, Glucose \>1.5\*ULN, Creatine Kinase \>2.0\*ULN, C Reactive Protein \>1.1\*ULN, Chol \>1.3\*ULN. Urinalysis: Specific Gravity \>1.030, Glucose, Ketones, Protein, Hg, Nitrite, Leu Esterase \>=1, Ery, Leu \>=20, Hyaline Casts \>1.Only those category in which at least 1 participant had data is reported.

Time frame:
From the first dose of study drug up to Week 18
Reported as:
Count of participants · Participants
Open-Label Phase: Number of Participants With Laboratory Abnormalities
ParticipantsTofacitinib: Open-Label Phase
Hemoglobin (<0.8* LLN)1
Hematocrit (<0.8* LLN)1
Erythrocytes (<0.8* LLN)2
Ery. Mean Corpuscular Volume (<0.9*LLN)3
Ery. Mean Corpuscular Volume (>1.1*ULN )4
Platelets (<0.5*LLN)1
Platelets (>1.75*ULN)2
Leukocytes (<0.6*LLN)1
Leukocytes (>1.5*ULN)2
Lymphocytes (<0.8*LLN)7
Lymphocytes (>1.2*ULN)2
Lymphocytes/Leukocytes (<0.8*LLN)15
Lymphocytes/Leukocytes (>1.2*ULN)20
Neutrophils (<0.8*LLN)8
Neutrophils (>1.2*ULN)18
Neutrophils/Leukocytes (<0.8*LLN)19
Basophils/Leukocytes (>1.2*ULN)37
Eosinophils (>1.2*ULN)53
Eosinophils/Leukocytes (>1.2*ULN)32
Monocytes (>1.2*ULN)3
Monocytes/Leukocytes (>1.2*ULN)38
Ery. Sedimentation Rate (>1.5*ULN)65
Bilirubin (>1.5*ULN)1
Indirect Bilirubin (>1.5*ULN)1
Aspartate Aminotransferase (AST) (>3.0*ULN)4
Alanine Aminotransferase (ALT) (>3.0*ULN)5
GGT (>3.0*ULN)1
Alkaline Phosphatase (>3.0*ULN)1
Albumin (>1.2*ULN)1
Creatinine (>1.3*ULN)1
HDL Cholesterol (<0.8*LLN)2
LDL Cholesterol (>1.2*ULN)4
LDL Chol Friedewald Est PEG (>1.2*ULN)1
Triglycerides (>1.3*ULN)27
Calcium (<0.9*LLN)1
Bicarbonate (<0.9*LLN)10
Glucose (>1.5*ULN)2
Creatine Kinase (>2.0*ULN)12
C Reactive Protein (>1.1*ULN)122
Cholesterol (>1.3*ULN)2
Specific Gravity (>1.030)32
URINE Glucose (>=1)1
Ketones (>=1)11
URINE Protein (>=1)9
URINE Hemoglobin (>=1)48
Nitrite (>=1)6
Leukocyte Esterase (>=1)59
URINE Erythrocytes (>=1)23
URINE Leukocytes (>=20)16
Hyaline Casts (>1)1
SecondaryDouble Blind Phase: Number of Participants With Laboratory Abnormalities

Criteria: Hg, hematocrit Ery; \<0.8\* LLN, Ery. Mean Corpuscular Volume; \<0.9\*LLN, \>1.1\* ULN, Platelets; \<0.5\*LLN, \>1.75\*ULN, leu; \<0.6\*LLN, \>1.5\*ULN, Ly, Ly/leu, Neutrophils, Neutrophils/leu \<0.8\*LLN, Basophils/leu, Eosinophils, Eosinophils/leu, Monocytes, Monocytes/leu \>1.2\*ULN, Prothrombin Time \>1.1\*ULN, Ery Sedimentation Rate \>1.5\*ULN. Bilirubin, Direct Bilirubin, Indirect Bilirubin \>1.5\*ULN, AST, ALT, Gamma Glutamyl Transferase (GGT), Alkaline Phosphatase \>3.0\*ULN, Albumin \>1.2\*ULN, Creatinine \>1.3\*ULN, HDL Cholesterol (Chol)\<0.8\*LLN, LDL Chol, LDL Chol Friedewald Est PEG \>1.2\*ULN, Triglycerides \>1.3\*ULN, Calcium \<0.9\*LLN, Bicarbonate \<0.9\*LLN, Glucose \>1.5\*ULN, Creatine Kinase \>2.0\*ULN, C Reactive Protein \>1.1\*ULN, Chol \>1.3\*ULN. Urinalysis: Specific Gravity \>1.030, pH \>8, urine Glucose, Ketones, Protein, Hg, Nitrite, Leu Esterase \>=1, Ery, Leu \>=20, Hyaline Casts \>1.Only those category in which at least 1 participant had data is reported.

Time frame:
From the first dose of study drug in double blind up to Week 44
Reported as:
Count of participants · Participants
Double Blind Phase: Number of Participants With Laboratory Abnormalities
ParticipantsTofacitinib: Double Blind PhasePlacebo
Hemoglobin (<0.8*LLN)13
Hematocrit (<0.8*LLN)02
Erythrocytes (<0.8*LLN)02
Ery. Mean Corpuscular Volume (<0.9*LLN)21
Ery. Mean Corpuscular Volume (>1.1*ULN)12
Platelets (<0.5*LLN)10
Leukocytes (<0.6*LLN)01
Leukocytes (>1.5*ULN)10
Lymphocytes (<0.8*LLN)51
Lymphocytes (>1.2*ULN)10
Lymphocytes/Leukocytes (<0.8*LLN)95
Lymphocytes/Leukocytes (>1.2*ULN)57
Neutrophils (<0.8*LLN)13
Neutrophils (>1.2*ULN)75
Neutrophils/Leukocytes (<0.8*LLN)56
Basophils (>1.2*ULN)10
Basophils/Leukocytes (>1.2*ULN)1415
Eosinophils (>1.2*ULN)2718
Eosinophils/Leukocytes (>1.2*ULN)2114
Monocytes (>1.2*ULN)22
Monocytes/Leukocytes (>1.2*ULN)1819
Prothrombin Time (>1.1*ULN)01
Ery. Sedimentation Rate (>1.5*ULN)2619
Bilirubin (>1.5*ULN)10
Direct Bilirubin (>1.5*ULN)10
Indirect Bilirubin (>1.5*ULN)10
Alanine Aminotransferase(>3.0*ULN)12
GGT (>3.0*ULN)10
HDL Cholesterol (<0.8*LLN)02
Triglycerides (>1.3*ULN)86
Potassium (>1.1*ULN)10
Calcium (<0.9*LLN )11
Glucose (>1.5*ULN)10
Creatine Kinase (>2.0*ULN)22
C Reactive Protein (>1.1*ULN)4447
Specific Gravity (>1.030)127
pH (>8)01
URINE Glucose (>=1)11
Ketones (>=1)710
URINE Protein (>=1)44
URINE Hemoglobin (>=1)2511
Nitrite (>=1)36
Leukocyte Esterase (>=1)2625
URINE Erythrocytes (>=20)106
URINE Leukocytes (>=20)66
Hyaline Casts (>1)11
Granular Casts (>1)01
Bicarbonate (<0.9*LLN)02
SecondaryOpen-Label Phase: Number of Participants With Physical Examination Abnormalities

Physical examination included: abdomen, ears, extremities, eyes, general appearance, head, heart, lungs, lymph nodes, neurological, nose, skin, and throat. Abnormality in physical examination was based on investigator's discretion.

Time frame:
Baseline, Weeks 2, 4, 8, 12 and 18
Reported as:
Count of participants · Participants
Open-Label Phase: Number of Participants With Physical Examination Abnormalities
ParticipantsTofacitinib: Open-Label Phase
Abdomen: Baseline1
Abdomen: Week 22
Abdomen: Week 43
Abdomen: Week 82
Abdomen: Week 122
Abdomen: Week 181
Ears: Baseline5
Ears: Week 20
Ears: Week 40
Ears: Week 80
Ears: Week 120
Ears: Week 183
Extremities: Baseline49
Extremities: Week 243
Extremities: Week 435
Extremities: Week 830
Extremities: Week 1228
Extremities: Week 1823
Eyes: Baseline2
Eyes: Week 20
Eyes: Week 40
Eyes: Week 80
Eyes: Week 120
Eyes: Week 182
General appearance: Baseline16
General appearance: Week 20
General appearance: Week 41
General appearance: Week 82
General appearance: Week 120
General appearance: Week 185
Head: Baseline3
Head: Week 20
Head: Week 40
Head: Week 80
Head: Week 120
Head: Week 184
Heart: Baseline0
Heart: Week 20
Heart: Week 40
Heart: Week 82
Heart: Week 120
Heart: Week 180
Lungs: Baseline1
Lungs: Week 21
Lungs: Week 40
Lungs: Week 81
Lungs: Week 121
Lungs: Week 180
Lymph nodes: Baseline2
Lymph nodes: Week 25
Lymph nodes: Week 45
Lymph nodes: Week 85
Lymph nodes: Week 123
Lymph nodes: Week 184
Neurological: Baseline4
Neurological: Week 21
Neurological: Week 40
Neurological: Week 80
Neurological: Week 120
Neurological: Week 184
Nose: Baseline0
Nose: Week 20
Nose: Week 40
Nose: Week 80
Nose: Week 120
Nose: Week 185
Skin: Baseline27
Skin: Week 20
Skin: Week 41
Skin: Week 81
Skin: Week 120
Skin: Week 1812
Throat: Baseline1
Throat: Week 20
Throat: Week 40
Throat: Week 80
Throat: Week 120
Throat: Week 186
SecondaryDouble Blind Phase: Number of Participants With Physical Examination Abnormalities

Physical examination included: abdomen, ears, extremities, eyes, general appearance, head, heart, lungs, lymph nodes, neurological, nose, skin, and throat. Abnormality in physical examination was based on investigator's discretion.

Time frame:
Weeks 18, 20, 24, 28, 32, 36, 40 and 44
Reported as:
Count of participants · Participants
Double Blind Phase: Number of Participants With Physical Examination Abnormalities
ParticipantsTofacitinib: Double Blind PhasePlacebo
Abdomen: Week 1801
Abdomen: Week 2011
Abdomen: Week 2411
Abdomen: Week 2800
Abdomen: Week 3200
Abdomen: Week 3600
Abdomen: Week 4000
Abdomen: Week 4400
Ears: Week 1830
Ears: Week 2000
Ears: Week 2400
Ears: Week 2800
Ears: Week 3200
Ears: Week 4001
Ears: Week 4400
Extremities: Week 18912
Extremities: Week 201114
Extremities: Week 2457
Extremities: Week 2866
Extremities: Week 3218
Extremities: Week 3626
Extremities: Week 4036
Extremities: Week 4437
Eyes: Week 1820
Eyes: Week 2000
Eyes: Week 2400
Eyes: Week 2800
Eyes: Week 3200
Eyes: Week 4000
Eyes: Week 4410
General appearance: Week 1823
General appearance: Week 2011
General appearance: Week 2400
General appearance: Week 2800
General appearance: Week 3200
General appearance: Week 4000
General appearance: Week 4410
Head: Week 1831
Head: Week 2000
Head: Week 2400
Head: Week 2800
Head: Week 3201
Head: Week 4010
Head: Week 4400
Heart: Week 1800
Heart: Week 2000
Heart: Week 2400
Heart: Week 2800
Heart: Week 3200
Heart: Week 3600
Heart: Week 4000
Heart: Week 4400
Lungs: Week 1800
Lungs: Week 2010
Lungs: Week 2410
Lungs: Week 2810
Lungs: Week 3200
Lungs: Week 3600
Lungs: Week 4001
Lungs: Week 4400
Lymph nodes: Week 1831
Lymph nodes: Week 2030
Lymph nodes: Week 2421
Lymph nodes: Week 2810
Lymph nodes: Week 3211
Lymph nodes: Week 3610
Lymph nodes: Week 4020
Lymph nodes: Week 4411
Neurological: Week 1831
Neurological: Week 2010
Neurological: Week 2400
Neurological: Week 2800
Neurological: Week 3200
Neurological: Week 4000
Neurological: Week 4411
Nose: Week 1840
Nose: Week 2000
Nose: Week 2400
Nose: Week 2800
Nose: Week 3200
Nose: Week 4000
Nose: Week 4410
Skin: Week 1884
Skin: Week 2031
Skin: Week 2410
Skin: Week 2800
Skin: Week 3200
Skin: Week 4011
Skin: Week 4442
Throat: Week 1842
Throat: Week 2001
Throat: Week 2400
Throat: Week 2800
Throat: Week 3200
Throat: Week 4000
Throat: Week 4400
SecondaryOpen-Label Phase: Number of Participants With Vital Sign Abnormalities

Vital Sign Abnormalities criteria included: sitting diastolic blood pressure millimeters of Mercury (mmHG) of \<50 mmHg, sitting pulse rate beats per minute (bpm) of \<40 or 120 bpm, sitting systolic blood pressure (mmHG) of \<90 mmHg, supine diastolic blood pressure (mmHG) of \<50 mmHg, supine pulse rate (BPM) of \<40 bpm or \>120 bpm, supine systolic blood pressure (mmHG) of 90 mmHg.

Time frame:
From the first dose of study drug up to Week 18
Reported as:
Count of participants · Participants
Open-Label Phase: Number of Participants With Vital Sign Abnormalities
ParticipantsTofacitinib: Open-Label Phase
Sitting diastolic BP ([mmHg]): <50 mmHg0
Sitting pulse rate (bpm): <40 bpm0
Sitting pulse rate (bpm): >120 bpm5
Sitting systolic BP (mmHg): <90 mmHg0
Supine diastolic BP (mmHg): <50 mmHg2
Supine pulse rate (bpm): <40 bpm0
Supine pulse rate (bpm): >120 bpm0
Supine systolic BP (mmHg): <90 mmHg2
SecondaryDouble Blind Phase: Number of Participants With Vital Sign Abnormalities

Vital Sign Abnormalities criteria included: diastolic blood pressure (mmHG) of \<50 mmHg, Pulse rate (BPM) of \<40 bpm or \>120 bpm, sitting diastolic blood pressure (mmHG) of \<50 mmHg, sitting pulse rate beats per minute (bpm) of \<40 bpm or \>120 bpm, sitting systolic blood pressure (mmHG) of \<90 mmHg, supine diastolic blood pressure (mmHG) of \<50 mmHg, supine pulse rate (BPM) of \<40 bpm or \>120 bpm, supine systolic blood pressure (mmHG) of \<90 mmHg, systolic blood pressure (mmHG) of \<90 mmHg.

Time frame:
From the first dose of study drug in double blind up to week 44
Reported as:
Count of participants · Participants
Double Blind Phase: Number of Participants With Vital Sign Abnormalities
ParticipantsTofacitinib: Double Blind PhasePlacebo
Diastolic BP (mmHg): <50 mmHg00
Pulse rate (bpm): <40 bpm00
Pulse rate (bpm): >120 bpm00
Sitting diastolic BP (mmHg): <50 mmHg00
Sitting pulse rate (bpm): <40 bpm00
Sitting pulse rate (bpm): >120 bpm01
Sitting systolic BP (mmHg): <90 mmHg00
Supine diastolic BP (mmHg): <50 mmHg00
Supine pulse rate (bpm): <40 bpm00
Supine pulse rate (bpm): >120 bpm00
Supine systolic BP (mmHg): <90 mmHg10
Systolic BP (mmHg): <90 mmHg00
SecondaryOpen-Label Phase: Number of Participants With Change From Baseline in Vital Sign Measures

Change in vital Signs included: Sitting diastolic blood pressure \[mmHG\]: \>=20mmHg increase from baseline (IFB) and \>= 20mmHg decrease from baseline (DFB). Sitting systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB. Supine diastolic blood pressure mmHG: \>= 20mmHg IFB and \>= 20mmHg DFB. Supine systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB.

Time frame:
From the first dose of study drug up to Week 18
Reported as:
Count of participants · Participants
Open-Label Phase: Number of Participants With Change From Baseline in Vital Sign Measures
ParticipantsTofacitinib: Open-Label Phase
Sitting diastolic BP: >= 20mmHg IFB9
Sitting diastolic BP: >= 20mmHg DFB14
Sitting systolic BP: >= 30mmHg IFB2
Sitting systolic BP: >= 30mmHg DFB5
Supine diastolic BP: >= 20mmHg IFB0
Supine diastolic BP: >= 20mmHg DFB3
Supine systolic BP: >= 30mmHg IFB0
Supine systolic BP: >= 30mmHg DFB3
SecondaryDouble Blind Phase: Number of Participants With Change From Baseline in Vital Sign Measures

Change in vital Signs included: Sitting diastolic blood pressure (mmHG): \>=20mmHg IFB and \>= 20mmHg DFB. Sitting systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB. Supine diastolic blood pressure mmHG: \>= 20mmHg IFB and \>= 20mmHg DFB. Supine systolic blood pressure mmHG: \>= 30mmHg IFB and \>= 30mmHg DFB.

Time frame:
From the first dose of study drug in double blind up to week 44
Reported as:
Count of participants · Participants
Double Blind Phase: Number of Participants With Change From Baseline in Vital Sign Measures
ParticipantsTofacitinib: Double Blind PhasePlacebo
Sitting diastolic BP: >= 20mmHg IFB93
Sitting diastolic BP: >= 20mmHg DFB79
Sitting systolic BP: >= 30mmHg IFB34
Sitting systolic BP: >= 30mmHg DFB02
Supine diastolic BP: >= 20mmHg IFB00
Supine diastolic BP: >= 20mmHg DFB00
Supine systolic BP: >= 30mmHg IFB00
Supine systolic BP: >= 30mmHg DFB00

Adverse events

Collected over From the first dose of study drug up to week 44. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib: Open-Label Phase0/225 (0%)7/225 (3.1%)108/225 (48%)
Tofacitinib: Double Blind Phase0/88 (0%)1/88 (1.1%)57/88 (64.8%)
Placebo0/85 (0%)2/85 (2.4%)57/85 (67.1%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventTofacitinib: Open-Label PhaseTofacitinib: Double Blind PhasePlacebo
AppendicitisInfections and infestations1/2250/881/85
IntussusceptionGastrointestinal disorders0/2250/881/85
Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders0/2250/881/85
Pilonidal sinus repairSurgical and medical procedures0/2251/880/85
Crohn's diseaseGastrointestinal disorders1/2250/880/85
DiarrhoeaGastrointestinal disorders1/2250/880/85
VomitingGastrointestinal disorders1/2250/880/85
Condition aggravatedGeneral disorders1/2250/880/85
Epidural empyemaInfections and infestations1/2250/880/85
PneumoniaInfections and infestations1/2250/880/85
Most frequent other events
Showing 10 of 45
Most frequent other events
EventTofacitinib: Open-Label PhaseTofacitinib: Double Blind PhasePlacebo
Disease progressionGeneral disorders5/2258/8813/85
Upper respiratory tract infectionInfections and infestations24/22513/889/85
Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders6/2253/8811/85
NasopharyngitisInfections and infestations10/2257/883/85
HeadacheNervous system disorders16/2252/886/85
NauseaGastrointestinal disorders13/2250/880/85
VomitingGastrointestinal disorders12/2250/884/85
PyrexiaGeneral disorders11/2254/881/85
ArthralgiaMusculoskeletal and connective tissue disorders5/2252/884/85
SinusitisInfections and infestations0/2254/881/85

Baseline characteristics

The open-label phase full analysis set (OLFAS) consisted of all participants who were enrolled into open-label phase of the study and received at least one dose of study medication in open-label phase.

Age, Continuous
Age, Continuous(Years)Tofacitinib: Open-Label Phase
Mean11.92 ± 4.06
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib: Open-Label Phase
Female169
Male56
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tofacitinib: Open-Label Phase
Hispanic or Latino64
Not Hispanic or Latino161
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tofacitinib: Open-Label Phase
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White196
More than one race0
Unknown or Not Reported24
08

Study locations

103 sites
  • Arkansas Children's Hospital - Attention: Jill Hernandez
    Little Rock, Arkansas 72202, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Loma Linda University Children's Hospital
    Loma Linda, California 92354, United States
  • Loma Linda University Clinical Trial Center
    Loma Linda, California 92354, United States
  • Loma Linda University Eye Institute
    Loma Linda, California 92354, United States
  • Loma Linda University General Pediatric Clinic - Meridian
    Loma Linda, California 92354, United States
  • Pediatric Specialty Team Centers of LLU Children's Hospital
    Loma Linda, California 92408, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Pediatric Specialty Team Centers of LU Children's Hospital
    San Bernardino, California 92408, United States
  • Rady Children's Hospital - San Diego
    San Diego, California 92123, United States
  • Rady Children's Hospital Center for Pediatric Clinical Research
    San Diego, California 92123, United States
  • Rady Children's Hospital Education and Office Building
    San Diego, California 92123, United States
  • Rady Children's Hospital Research Pharmacy
    San Diego, California 92123, United States
  • Rady Children's Hospital Rheumatology Clinic
    San Diego, California 92123, United States
  • Connecticut Children's Medical Center -Pharmacy
    Hartford, Connecticut 06106, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • IDS Pharmacy Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
  • Children's Healthcare of Atlanta-Pediatric Research Center
    Atlanta, Georgia 30322, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Children's Specialty Services
    Atlanta, Georgia 30322, United States
  • Augusta University Health Pharmacy
    Augusta, Georgia 30912, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • IU Health Investigational Drug Services
    Indianapolis, Indiana 46202, United States
  • Riley Hospital for Children at IU Health
    Indianapolis, Indiana 46202, United States
  • Tufts Medical Center Floating Hospital for Children
    Boston, Massachusetts 02111, United States
  • Journey Clinic: Center for Children with Cancer and Blood Diseases, Uni. of Minnesota Medical Centre
    Minneapolis, Minnesota 55454, United States
  • Pediatric Specialty Care Explorer Clinic, University of Minnesota, Medical Center
    Minneapolis, Minnesota 55454, United States
  • University of Minnesota Medical Center, Fairview IDS Pharmacy
    Minneapolis, Minnesota 55455, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Pharmacy Department
    Bronx, New York 10467, United States
  • Cohen Children's Medical Center of NY
    Lake Success, New York 11042, United States
  • Cohen Children's Medical Center of New York
    New Hyde Park, New York 11040, United States
  • Columbia University Medical Center - Herbert Irving Pavilion
    New York, New York 10032, United States
  • Children's Specialty Center
    Charlotte, North Carolina 28203, United States
  • Carolinas HealthCare System IDS Pharmacy
    Charlotte, North Carolina 28204, United States
  • Pediatric Research
    Charlotte, North Carolina 28207, United States
  • Cincinnati Childrens Hospital Medical Center
    Cincinnati, Ohio 45229-3039, United States
  • Legacy Emanuel Medical Center - Inpatient Pharmacy
    Portland, Oregon 97227, United States
  • Randall Children's Hospital at Legacy Emanuel
    Portland, Oregon 97227, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Dell Children's Medical Center of Central Texas
    Austin, Texas 78723, United States
  • Specially for Children, Dell Children's Medical Center of Central Texas
    Austin, Texas 78723, United States
  • Texas Children's Hospital - Clinical Care center
    Houston, Texas 77030, United States
  • Texas Children's Hospital - Clinical Research Center
    Houston, Texas 77030, United States
  • Texas Children's Hospital - Investigational Pharmacy
    Houston, Texas 77030, United States
  • Texas Children's Hospital - Main Hospital
    Houston, Texas 77030, United States
  • Texas Children's Hospital/Baylor College of Medicine - Feigin Center
    Houston, Texas 77030, United States
  • PCH Pharmacy - Primary Children's Hospital - Pharmacy
    Salt Lake City, Utah 84113, United States
  • Primary Children's Hospital
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Instituto CAICI SRL
    Rosario, Santa FE S2000PBJ, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucuman, Tucuman T4000AXL, Argentina
  • Hospital Britanico de Buenos Aires
    Caba, C1280AEB, Argentina
  • The Sydney Children's Hospital Network Westmead
    Westmead, New South Wales 2145, Australia
  • The Royal Children's Hospital
    Parkville, Victoria 3052, Australia
  • UZ Leuven-Gasthuisberg
    Leuven, 3000, Belgium
  • SER - Servicos Especializados em Reumatologia
    Salvador, Bahia 40150-150, Brazil
  • CMIP -Centro Mineiro de Pesquisa Ltda / Reumatocenter
    Juiz de Fora, MG 36010-570, Brazil
  • Santa Casa de Misericordia de Belo Horizonte
    Belo Horizonte, Minas Gerais 30150-220, Brazil
  • Santa Casa de Misericordia de Belo Horizonte
    Belo Horizonte, Minas Gerais 30150-320, Brazil
  • Hospital Pequeno Principe / A ssociacao Hospitalar de Protecao a Infancia
    Curitiba, Parana 80250-060, Brazil
  • Instituto de Pesquisa Pele Pequeno Principe
    Curitiba, Parana 80250-060, Brazil
  • Instituto de Puericultura e Pediatria Martagao Gesteira
    Rio de Janeiro, RJ 21941-912, Brazil
  • Faculdade de Medicina da UNESP
    Botucatu, SAO Paulo 18618-686, Brazil
  • SPDM- Associacao Paulista para o Desenvolvimento da Medicina-Hospital Sao Paulo
    Sao Paulo, 04037-002, Brazil
  • Instituto da Crianca do Hospital das Clinicas da FMUSP
    Sao Paulo, 05409-011, Brazil
  • Alberta Children's Hospital - Inpatient Pharmacy
    Calgary, Alberta T3B 6A8, Canada
  • Alberta Children's Hospital/University of Calgary
    Calgary, Alberta T3B 6A8, Canada
  • Children's & Women's Health Centre of B.C.
    Vancouver, British Columbia V6H 3N1, Canada
  • British Columbia Children's Hospital
    Vancouver, British Columbia V6H 3V4, Canada
  • McGill University Health Canter, Glen site, Pharmacy
    Montreal, Quebec H4A 3J1, Canada
  • McGill University Health Center, Glen Site, Center for Innovative Medicine
    Montreal, Quebec H4A 3J1, Canada
  • Rambam Health Care
    Haifa, 3109601, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Chaim Sheba M.C Tel hashomer
    Ramat Gan, 52621, Israel
  • Clinica de Investigacion en Reumatologia y Obesidad, S.C.
    Guadalajara, Jalisco 44650, Mexico
  • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C.
    San Luis Potosi, 78213, Mexico
  • Sociedad de Beneficencia Espanola, A.C.
    San Luis Potosi, 78250, Mexico
  • Hospital Central "Dr. Ignacio Morones Prieto"
    San Luis Potosi, 78290, Mexico
  • Unidad de Investigaciones Reumatologicas A.C.
    San Luis Potosi, 78290, Mexico
  • Wojewodzki Szpital Dzieciecy im. J. Brudzinskiego
    Bydgoszcz, 85-667, Poland
  • FSAEI HE I.M. Sechenov First MSMU of Minzdrav of Russia (Sechenovskiy University)
    Moscow, 119435, Russian Federation
  • FSAEI HE I.M Sechenov First MSMU of Minzdrav of Russia (Sechenovskiy University)
    Moscow, 119991, Russian Federation
  • FSAI "NSPCCH" of Minzdrav of Russia
    Moscow, 119991, Russian Federation
  • FSBEI HE "St. Petersburg State Pediatric Medical University"
    Saint-Petersburg, 194100, Russian Federation
  • State Budgetary Healthcare Institution of Samara Region "Tolyatti City Clinical Hospital #5"
    Tolyatti, 445039, Russian Federation
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario y Politecnico La Fe
    Valencia, 46026, Spain
  • Hacettepe University Medical Faculty
    Ankara, 06100, Turkey
  • Istanbul Medeniyet University Medical Faculty
    Istanbul, 34000, Turkey
  • Istanbul University Cerrahpasa Medical Faculty
    Istanbul, 34098, Turkey
  • Umraniye Training and Research Hospital
    Istanbul, 34764, Turkey
  • Erciyes University Medical Faculty
    Kayseri, 38039, Turkey
  • Ivano-Frankivsk Regional Children's Clinical Hospital
    Ivano-Frankivsk, 76014, Ukraine
  • Vinnytsia Regional Children's Clinical Hospital
    Vinnytsia, 21000, Ukraine

Showing the first 100 of 103 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, Vyzhga Y, Marzan K, Grebenkina L, Tirosh I, Imundo L, Jerath R, Kingsbury DJ, Sozeri B, Vora SS, Prahalad S, Zholobova E, Butbul Aviel Y, Chasnyk V, Lerman M, Nanda K, Schmeling H, Tory H, Uziel Y, Viola DO, Posner HB, Kanik KS, Wouters A, Chang C, Zhang R, Lazariciu I, Hsu MA, Suehiro RM, Martini A, Lovell DJ; Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG). Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021 Nov 27;398(10315):1984-1996. doi: 10.1016/S0140-6736(21)01255-1. Epub 2021 Nov 9. PubMed 34767764 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in May 2019, 35 months.

Results were first posted in Feb 2020, 9 months after primary completion.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2015
First posted
Oct 30, 2015
StartActual
Jun 10, 2016
Primary completionActual
May 16, 2019
CompletionActual
May 16, 2019
Results first posted
Feb 21, 2020
Last update
Apr 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02592434
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 30, 2015
Start date
Jun 10, 2016
Primary completion
May 16, 2019
Completion
May 16, 2019
Results posted
Feb 21, 2020
Last update
Apr 13, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion